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                                                                  ABSTRACT 
 
The human prostate is an accessory male reproductive gland located below the neck of the urinary 
bladder. Benign prostatic hyperplasia (BPH) and prostate cancer are the frequently encountered 
pathological conditions of the prostate. It is estimated that 50% of men will develop BPH by age 
50 with the incidence increasing to 90% by age 90. Prostate cancer is the second most common 
cause of cancer in men worldwide after lung cancer. In this study, we examined the ability of 
synchrotron radiation propagation phase-contrast computerized tomography (PC-CT) in 
comparison to ultrasound (US), magnetic resonance imaging (MRI) and histology, to characterize 
and differentiate various structural features and pathological lesions in 61 prostate tissues from 13 
human patients collected during trans-urethral resection of the prostate. We compared the PC-CT, 
MRI, US and histology images of the same tissues from the same plane to determine if different 
structures like blood vessels, dilated acini etc. could be observed with each modality. The PC-CT 
was found to be a powerful imaging technique compared to MRI and US in identifying and 
resolving small structures located near each other. With PC-CT imaging, the same structures could 
be correctly identified almost 4 times and 15 times more often than MRI and US respectively. 
While comparing the ability to identify and resolve the nearby structures in PC-CT images 
reconstructed from 100%, 50% and 25% of the number of total projections collected (i.e. 2250 
projections over 180 degree rotation of a sample on imaging stage), the ranking was as follows: 
100% PC-CT>50% PC-CT>25% PC-CT (p<0.05). Radiation data recorded during a previous 
study while imaging dog cadavers with PC-CT were also analyzed. It was found that the average 
effective radiation dose imparted in a medium-sized dog during PC-CT imaging of one view of 
7.8 mm height with 2000 projections in the biomedical imaging and therapy – insertion device 
(BMIT-ID) beamline of Canadian light source (CLS) beamline was 1,481.7 mSv, which is very 
high compared to the standard clinical CT examination deposits in human clinical medicine. The 
dose could be reduced by performing sparse view imaging i.e. 50% projection PC-CT or 25% 
projection PC-CT, but these amounts are still hazardous, such that a similar protocol used in human 
would have the potential to induce cancer later in life in approximately 0.5 % of the patients. For 
PC-CT imaging of human prostate in situ, a human positioning device was also designed. Due to 
the limitation in the weight-bearing capacity of the stage in the beamline, the positioning device 
was designed to be able to hold only a human pelvis or pelvis phantom up to 50 kg of weight in an 
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upright position.  The results from this work demonstrate that the synchrotron radiation-based 
inline PC-CT is a promising technique that offers closer-to-histology grade non-invasive 
diagnostic imaging of prostate tissue. Further study in conducting in-vivo prostate imaging to 
reduce the radiation dose is the next step to move forward in this direction.  
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1. Introduction 
 
The human prostate gland is an accessory male reproductive gland located below the neck of the 
urinary bladder surrounding the most proximal part of the urethra. This tubulo-alveolar prostate 
gland secretes a slightly alkaline fluid, which helps to nourish as well as to transport the sperm 
with the help of its smooth muscle contractions during ejaculation. Prostatitis, benign prostatic 
hyperplasia and prostate cancer are the most frequently encountered pathological conditions of the 
prostate. It is estimated that 50% of men will develop BPH by age 50 with the incidence increasing 
to 90% by age 90 (Berry et al., 1984). Prostate cancer is the second most common cause of cancer 
in men after lung cancer and fifth leading cause of death worldwide (Bray et al., 2018). In Canada, 
prostate cancer is the most common cancer found in men. Out of all cancer related death, prostate 
cancer death represents 10.6%. Most of the prostate cancer cases (98%)  and almost all prostate 
cancer death (99%) are found in men with age more than 50 years% (Government of Canada, 
2019). 
Histology is considered the gold standard method to achieve an accurate diagnosis of prostate 
cancer but requires obtaining multiple invasive core biopsies with risky complications such as 
bleeding, infection, pain in the hypogastrium, perineum or urethra as well as urethral obstruction 
due to blood clots or post-biopsy prostate swelling, which often require multiple urethral 
catheterization. Therefore, histological examination is only done in the patients who are suspected 
of having prostate cancer based on non-invasive diagnostic techniques such as examining prostate-
specific antigen (PSA) levels in blood and medical imaging like ultrasound (US) and magnetic 
resonance imaging (MRI). However, each of the above techniques have considerable limitations 
rendering low diagnostic accuracy.  
PSA level is elevated in prostate cancer (Cooner et al., 1990). However, elevated PSA level is also 
detected in some other conditions like prostatic inflammation, BPH, after recent digital 
examination and after ejaculation (Herschman et al., 1997; Lee et al., 2012; Sershon et al., 1994; 
Smith et al., 1996). Approximately 15% of prostate cancer cases are also missed with PSA 
screening (Thompson et al., 2004). Similarly, MRI has high sensitivity (93%; proportion of true 
positives out of all tested positive) but low specificity (41%; proportion of true negative out of all 
tested negative) and US has high specificity (96%) but low sensitivity (48%) (Ahmed et al., 2017). 
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So, the development of a superior non-invasive diagnostic imaging technique is immensely 
needed.  
In a previous preliminary imaging study on ex-vivo whole dog prostates, we had found that 
synchrotron-based PC-CT resulted in better visualization of structure details compared to US, CT, 
and MRI, but not histology. However, in this study, we have applied PC-CT imaging to excised 
human prostate TURP (Trans Urethral Resection of Prostate) samples from BPH suspected 
patients to quantify the quality of the PC-CT images compared to US, MRI and histology. We 
didn’t image our tissue samples with the conventional absorption-based CT because the CT images 
of the prostate glands from the previous study showed very limited amounts of detail. Moreover, 
the TURP tissue samples are believed to be too thin to absorb x-rays, so to produce useful image 
characteristics. We have also evaluated PC-CT imaging and image quality following 
reconstructing with a reduced number of projections (sparse view image reconstruction technique). 
This is important because imaging with a lower number of projections will reduce image 
acquisition time and radiation dose, which is critical for the transition towards the clinical 
application of the PC-CT. Radiation data previously collected by our team during PC-CT imaging 
of canine cadavers has also been evaluated to determine the radiation dose a cadaver receives 
during imaging and also to calculate the radiation dose that would be received during 
corresponding sparse-view imaging.  Finally, a design has been developed for a human positioning 
device (pelvic holder) to hold a human pelvis or pelvis phantom with a real prostate inside it to 
image in the synchrotron to see how PC-CT images of a prostate inside a human body look like. 
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2. Literature review 
1.1 Prostate gland anatomy, histology, and physiology 
 
The human prostate gland is an accessory male reproductive gland located below the neck of the 
urinary bladder surrounding the most proximal part of the urethra (Figure 2.1). The gland is 
posterior to the pubic symphysis and anterior to the rectum (Bhavsar & Verma, 2014) making it 
accessible to digital rectal palpation for clinical examination. The tubulo-alveolar prostate gland 
secretes a slightly alkaline fluid which helps nourish and transport sperm during ejaculation 
(Hunter, 1968; Kumar & Majumder, 1995). In human beings the gland is  a walnut-shaped 
structure with weight ranging from 7 to 16 grams (Leissner & Tisell, 1979). The gland consists of 
a base and an apex where the base is attached to the neck of the bladder and the apex lies on and 
is supported by the superior surface of the urogenital diaphragm. The prostate is encapsulated by 
an outer fibromuscular pseudo-capsule which is incomplete anteriorly at its apex (Ayala et al., 
1989; Udeh, 1982). The invasion of this fibromuscular band by neoplastic cells is indicative of 
malignancy and is considered clinically significant (Ayala et al., 1989). The fibromuscular capsule 
sends off strands of connective tissue exteriorly which attach to peri-prostatic tissue structures 
(Ayala et al., 1989).  
 
2.1 Schematic diagram showing the location of the prostate gland and its surrounding structure in 
sagittal section of human male body. (Source “Penile Anatomy-CTHP Image”, March 2015. 
Retrieved from National Cancer Institute, on January 2019, 
https://visualsonline.cancer.gov/details.cfm?imageid=9988. Reprinted with permission.) 
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Blood is supplied to the prostate gland by the branches of the internal iliac artery and the gland 
receives innervation through the prostatic plexus. Lymph from the prostate mainly drains into the 
internal iliac and sacral lymph nodes (Bhavsar & Verma, 2014). Surgical removal of prostate 
cancer or the gland itself may affect the nerve supply to the bladder and penis eventually causing 
problems in urination and sexual function (Michaelson et al., 2008). 
 
 
 
Figure 2.2 Schematic diagram showing different zones of human prostate gland. PZ: peripheral 
zone, CZ: central zone, TZ: transitional zone and FM: anterior fibromuscular zone (Dhakal 
Subash, 2019). 
Histologically, the prostate gland is divided into four zones; transitional, central, peripheral and 
anterior fibromuscular (Figure 2.2) (McNeal, 1968). The first three are considered glandular zones 
and contain supportive stroma while the fourth is non-glandular and only contains fibromuscular 
stroma. The transitional zone is the most central part of the gland and surrounds the distal part of 
the pre-prostatic urethra. The central zone is the part of the prostate gland which encircles the 
ejaculatory ducts and contains 20-25% of the glandular mass of the prostate.  The peripheral zone 
of the prostate gland is the largest comprising about 70-75% of the total glandular mass. This zone 
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is located on the posterior-lateral aspects of the gland and is the part which is palpated when a 
digital rectal examination is performed. The smallest zone of the prostate is the anterior 
fibromuscular zone which is devoid of glandular tissue and is comprised of fibrous connective 
tissue and smooth muscles (McNeal, 1968). These four zones not only have different 
embryological origin, anatomical location and biological function but are also susceptible to 
difference pathological conditions.  Around 70% of all prostate cancer cases arise within the 
peripheral zone and the majority of BPH cases originate from the transitional zone (Lee et al., 
2011). 
The prostate contains an outer thin circular smooth muscle layer and an inner thick longitudinal 
smooth muscle layer that continue interiorly and blends with the fibromuscular stroma surrounding 
and supporting the glandular structures.  (Udeh, 1982). There are around 30-50 tubulo-acinar 
glands within the prostate. This acini-duct system is lined by a layer of basal cells and a layer of 
secretory columnar epithelium of varying height which later becomes transitional epithelium at 
the entrance of the prostatic urethra (McNeal, 1988) (Figure 2.3).  
 
 
Figure 2.3 Histological image showing a microscopic view of the moral human prostate with 
clear visualization of fibromuscular stroma (green arrows), acini or glands, and epithelium. 
(Source “Prostate”, Retrieved from The Human Protein Atlas, on January 2020, 
https://www.v19.proteinatlas.org/learn/dictionary/normal/prostate/detail+1 . Reprinted with 
permission.) 
 
In humans, the prostate gland contributes 30% of the seminal fluid which not only helps nourish 
and transport the spermatozoa but also acts as a buffer against the adverse acidic environment of 
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the female genitalia. This prostatic secretion is rich in citric acid and zinc, the concentrations of 
which are 75 and 1000 times greater in prostatic fluid than plasma, respectively. The cells of the 
peripheral zone of the prostate are rich in these two components and are their main source in semen. 
(Franklin, et al., 2005a) 
 
2.1.Pathological conditions of prostate gland 
 
A prostate with a volume less than 30 cm3 is considered normal. Prostatic volume can be calculated 
by measuring prostatic length, width and height utilizing transrectal ultrasound (TRUS) and using 
the formula: 
Prostate size = 0.52 x length x width x height  
A prostate with a volume larger than 30 cm3  is considered to be exhibiting prostatomegaly 
(Gossner, 2012) which may be due to one of the following pathological conditions: prostatitis, 
benign prostatic hyperplasia, and prostate cancer. These conditions are the most frequently 
encountered pathological conditions of the prostate and are the most studied.  
2.1.1. Prostatitis 
 
Prostatitis is the inflammation of prostate gland and is classified into 4 different subtypes by the 
National Institute of Diabetes and Digestive and Kidney Diseases (Krieger et al., 1999). These are 
acute bacterial prostatitis, chronic bacterial prostatitis, chronic non-bacterial prostatitis/chronic 
pelvic pain syndrome and asymptomatic inflammatory prostatitis. The nature of pain and the 
duration of symptoms are often helpful in the initial diagnosis of prostatitis; however, additional 
tests are often required to confirm diagnosis such as bacterial culture and microscopic analysis of 
urine to identify bacteria and white blood cells (WBCs), respectively. The first two type of 
prostatitis, i.e. bacterial acute and chronic prostatitis are usually treated with antibiotics. The most 
common subtype of prostatitis is chronic non-bacterial prostatitis which represents ~95% of all 
prostatitis cases. This condition is difficult to diagnose clinically because of its vague symptoms. 
The diagnosis is also made after urine bacterial culture yields negative results (Krieger et al., 1999).   
Although it is recommend that antibiotic treatment be reserved for patients with bacterial 
prostatitis, it has been found that large number of prostatitis patients receive antibiotics (Collins et 
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al., 1998). The plasma level of prostate-specific antigen (PSA), a marker of prostate disease, often 
increases in all subtypes of prostatitis but the increase usually does not exceed twice the normal 
level  (Potts, 2001). 
2.1.2. Benign prostatic hyperplasia  
 
Benign prostatic hyperplasia is a non-neoplastic condition resulting in increased prostatic size the 
incidence of which increases with age. The prevalence of BPH is around 8% in the 4th decade of 
life while it increases to around 50% in the 6th decade and is more than 90% in men older than 70 
(Patel & Parsons, 2014). BPH most often arises from the transitional zone of the prostate gland 
and can result in the proliferation of glandular and stromal tissues with the former being more 
common. (Roehrborn, 2008; Wasserman, 2006). Budding and branching of the duct-acini system 
is the hallmark feature of glandular BPH. The hyperplastic gland has a bi-layered epithelial lining 
with outer cuboidal cells and inner tall columnar cells. In advanced stages of BPH basal cell 
hyperplasia of ducts and acini is seen which can be visualized utilizing basal cell specific stains 
(McNeal, 1965, 1988) 
The exact cause of BPH is not known although it is widely accepted that androgens play an 
important role in the development of this condition (Banerjee et al., 2018). Historically double 
castration was a treatment option in men with BPH because the procedure often resulted in 
reduction of the size of the lesion. This effect was thought to be related to the loss of androgen 
stimulation after castration (White, 1895). Androgens, however, may not be the only factor 
contributing to the development of BPH since most elderly men affected by this condition have 
low androgen levels (Ho & Habib, 2011). 
Despite not being a lethal condition, BPH can significantly reduce the quality of life in the elderly 
and results in high financial burden from continuous medical intervention. Clincally, BPH is 
known to result in a constellation of symptoms collectively known as the lower urinary tract 
syndrome (LUTS), which include difficulty voiding urine with patients reporting feeling the need 
to urinate frequently but with only little amount or weak stream of urine produced and waking up 
frequently at night to urinate. Dribbling of urine from the penis after urinating and blood in urine 
have also been described. More than 50% of BPH patients display LUTS symptoms particularly 
as they advance in age (McVary, 2006). These symptoms are all related to bladder outlet 
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obstruction (BOO) secondary to BPH (Jarvis et al., 2014) and are often accompanied with other 
symptoms such as  abdominal pain and pain during micturition. Incomplete urination in turn often 
results in ascending bacterial urinary tract infections (Truzzi et al., 2008). 
2.1.2.1.Diagnosis 
 
The diagnosis of BPH is often based on history and clinical symptoms, physical examination and 
laboratory testing. If BPH is suspected based on clinical signs, digital rectal examination is 
performed to assess the size and contour of the prostate gland. A smoothly enlarged symmetric 
prostate is indicative of BPH while an asymmetric, firm nodular prostate is an indicative of 
malignancy (Kim et al., 2015). 
Routinely used laboratory diagnostic tests for BPH include urinalysis and assessing the levels of 
PSA in the blood. Urinalysis in the suspected patient is for the evaluation of glucosuria, pyuria, 
and hematuria and is performed to help differentiate BPH from other possible causes of LUTS. 
Glucosuria, pyuria, and hematuria are suggestive of diabetes, urinary tract infection and urogenital 
malignancies respectively (Kim et al., 2015). 
PSA is an androgen-regulated glycoprotein produced by the epithelial cells of the prostate gland. 
After its secretion into the glandular lumen, PSA helps liquefy the semen by cleaving two proteins; 
semenogelin I and II, responsible for semen coagulation. This in turn eases sperm motility allowing 
the sperm to swim more freely (Balk et al., 2003).  
Normally, PSA is also present in the blood but in a very small amount, and less than or equal to 4 
ng PSA/mL blood is considered as normal (Adams, 2013). Disruption of prostatic tissue structure 
allows leaking of PSA into systemic circulation in a larger amount and will be detected in blood 
PSA testing (Sardana & Diamandis, 2012). PSA levels rise in BPH cases, thus increased level of 
PSA will suggest BPH. But, PSA does increase in prostate cancer also, so it is really difficult to 
differentiate whether the elevation is due to BPH or prostate cancer (Sershon et al., 1994). PSA 
level also increases after the ejaculation (Herschman et al., 1997; Rajaei et al., 2013) and 
inflammation of prostate (Lee et al., 2012). Therefore, confirmation of BPH is not possible based 
only on PSA, but PSA is, of course, a very useful tool for the diagnosis of BPH when used with 
other techniques. 
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Other diagnostic tests which are not routinely performed include urine cytology, serum creatinine, 
trans-rectal ultrasound, post-void residual urine test, cystourethroscopy and urodynamic studies.    
Although TRUS has the ability to determine the exact size of the prostate providing an accurate 
diagnosis of BPH, the technique is not routinely used because it is comparatively painful. 
2.1.3. Prostate cancer 
 
Prostate cancer can arise from the uncontrolled multiplication of glandular or stromal cells within 
the prostate with the former being most common representing 80% of diagnosed cases (Franz et 
al., 2013). Prostate cancer is the second most common cause of cancer worldwide. The majority  
of prostate cancer cases (around 99%) are diagnosed  in men over  50 years old (Stewart & Wild, 
n.d.) and arise from the peripheral zone of the prostate (Oh et al., 2003) 
 
Several genes and proteins have been found to be dysregulated in prostate cancer and these include 
Z1P1 protein (main zinc uptake transporter),  PTEN gene (a tumor-suppressor gene), insulin-like 
growth factors I and II (IGF-I and -II) and epidermal growth factor (EGF)  ( Oh et al., 2003; 
Franklin et al., 2005a; Franklin et al., 2005b).  
 
Androgens are thought to play an important role in the development of prostate cancer. Therefore, 
androgen deprivation therapy (ADT) is commonly used as a treatment option. ADT is performed 
through antiandrogen medications (androgen receptor blocker) or by chemical castration 
(androgen production suppressor) and was first introduced in 1941 with dramatic results (Huggins 
& Hodges, 1941). The use of ADT is, however, controversial, as the continued treatment results 
in  cancer cells eventually becoming resistant after 2-3 years  (Sharifi et al., 2005; Harris et al., 
2009; Das, 2017).  
 
Dietary habit, lifestyle exercise and genetics. have been found to be associated with the occurrence 
of prostate cancer (Anand et al., 2008). For example, men consuming a diet deficient in vitamin D 
or large quantities of red meat have a higher risk of developing prostate cancer (Wigle et al., 2008). 
Obesity is also a well-known risk factor for prostate cancer (Calle et al., 2003). Additionally, men 
with one first-degree relative affected by prostate cancer have a two-fold increase in the risk of 
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developing prostate cancer. The risk increases to fivefold if two first degree relatives are affected 
(Steinberg et al., 1990; Zhang et al., 2003).  
Prostate cancer is a slow growing cancer with no or few symptoms in early stages. Clinical signs 
can vary among affected men but are often related to the effects of the tumor on the lower urinary 
tract, the dysfunction of which depends on the severity of and size of the tumor.   Common clinical 
symptoms include difficulty in starting urination, burning sensation during urination, blood in 
urine and erectile dysfunction. When distant metastasis occurs, other clinical signs can appear 
related to the site of metastasis (Hamilton & Sharp, 2004; J. et al., 1998). 
2.1.3.1.Diagnosis 
 
The diagnosis of prostate cancer starts with the patient’s clinical history and the assessment of 
clinical symptoms. This is later followed by digital rectal examination (DRE) through which the 
peripheral zone of the prostate (its outer portion) can be assessed by putting a finger inside the 
rectum. Finding an asymmetric, firm nodule in the prostate is suggestive of prostate cancer (Kim 
et al., 2015). It has been found that approximately 70% of all prostate cancer cases arise from the 
peripheral zone of the prostate, while only 20% and 10% arise from the transitional and central 
zones, respectively (C. H. Lee et al., 2011; Loch, 2007).  The sensitivity of DRE in detecting 
prostate cancer is relatively low. One study reported that DRE could only detect 55.8% of prostate 
cancer cases (Schroder et al., 1998). The study also suggested that the positive predictive value 
and sensitivity of DRE are directly related to the PSA level. Another larger meta-analysis of several 
studies of men older than 50 years of age reported that the sensitivity, specificity, and positive 
predictive value of DRE was 53.2%, 83.6%, and 17.8% (Mistry & Cable, 2003). 
The level of PSA in the blood is often assessed during the initial screening for prostate cancer. It 
has been suggested that a PSA level above 4.0 ng/ml is suggestive of prostate cancer (Cooner et 
al., 1990). However, blood PSA level is known to increase in other prostatic diseases and also with 
age (Wolff et al., 1999). In fact, it has been shown that only 25% of patients with elevated blood 
PSA level have prostate cancer (Ichael & Arry, 2001; Sardana & Diamandis, 2012). Despite the 
high PSA level, prostate cancer in asymptomatic patients may not progress at all or progresses in 
such a slow manner that a patient may remain asymptomatic for rest of his life (Moyer, 2012). 
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Prostate cancer has been diagnosed in men with normal or low blood PSA level.  In fact, it is 
estimated that 15% of prostate cancer cases are diagnosed in patients with normal or even low 
blood PSA level (I. M. Thompson et al., 2004).  
PSA velocity, PSA density, and complexed PSA (cPSA) to free PSA (fPSA) ratio can also be 
assessed in people suspected of having prostate cancer where an elevation of these parameters can 
be indicative of malignancy (Djavan et al., 1999; ElShafei et al., 2013; Jung et al., 2006). 
Other non-invasive diagnostic modalities often pursued to diagnose prostate cancer include 
ultrasound and magnetic resonance imaging (MRI). However, histopathology is considered the 
gold standard method. Each of the three above diagnostic techniques will be discussed later in 
more depth. To date, synchrotron radiation phase contrast computerized tomography (PC-CT) has 
not been utilized to image the human prostate. PC-CT is the focus of this thesis and will be 
discussed at the end. 
2.2.Non-invasive diagnostic techniques:  
 
Trans-rectal ultrasound: This technique uses high-frequency sound wave emitted from a probe 
inserted inside the rectum facing the prostate. This technique is often performed after suspecting 
an abnormality in the prostate thorough DRE or after detecting a high PSA level in the blood. The 
shape and size of the prostate can be assessed accurately using TRUS but the technique has low 
sensitivity, specificity, and accuracy for the detection of prostate cancer and  is often used to obtain 
a guided prostate biopsy (Harvey et al., 2012a). In most cases of prostate cancer (60-70%), 
hypoechoic foci are seen in the peripheral zone of the prostate gland. However, it has been shown 
that only 17–57% of echo-poor foci are malignant (Harvey et al., 2012b; Spajic et al., 2007).  It is 
estimated that 30–40% of prostate cancer cases are isoechoic while hyperechoic cases are rare. 
Detecting prostate asymmetry, increased vascularity, bulging in the surface of the gland or breach 
in the capsule can be suggestive of prostate cancer. Hypoechoic spots can also be indicative of 
prostatitis and infarction (Harvey et al., 2012a; Taneja, 2004). Enhanced ultrasound imaging 
techniques such as color doppler TRUS and contrast-enhanced TRUS provide better sensitivity 
and specificity but are still mostly used to obtain a guided biopsy (Heijmink et al., 2006).  
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Magnetic resonance imaging: This technique utilizes a powerful magnetic field to produce a 
detailed picture of an imaged organ. MRI uses non-ionizing radiation and is, therefore, considered 
safer than X-ray imaging in which ionizing radiation is used. Still, MRI cannot be used in patients 
with biomedical implants (Hartwig et al., 2009). Protons (hydrogen nuclei) are present in every 
organ in the body incorporated into fat, protein and water. When a strong magnetic field is 
introduced through an MRI machine, these protons align with that field. When a radiofrequency 
pulse is introduced through the machine, protons are forced to spin out of equilibrium. Once the 
radiofrequency pulse is turned off, protons align back with the magnetic field releasing 
electromagnetic energy. The time protons take to realign with the magnetic field and energy 
released during that procedure are the basis of organ or tissue differentiation in MRI imaging. The 
time it takes for protons to revert to resting state can be measured in two different ways producing 
two different images (i.e. T1-weighted images and T2-weighted images) of the same organ with 
each having a different quality. (Berger, 2002). T1-weighted images are often used to assess bone 
and lymph node metastasis of prostatic cancer as well as post-biopsy prostatic hemorrhage. The 
zonal anatomy of the prostate is better assessed with T2-weighted images which are essential  in 
the detection and staging of prostate cancer (Akin & Hricak, 2007; Sala et al., 2006).  
A foci of low signal intensity within the peripheral zone of the prostate is suggestive of prostate 
cancer.  However, other pathological conditions such as inflammation, fibrosis, BPH, scars, and 
calcifications may also produce low signal intensity (Barentsz et al., 2012; Bonekamp et al., 2011). 
Additionally, T2 weighted images can’t differentiate a cancerous lesion located at the center of the 
prostate as a low signal spot in this location is likely due to BPH. The above limitations of T2 
weighted MRI explain why this technique has low specificity (37–53%) but relatively high 
sensitivity (75–94%) in detecting prostate cancer   (Murphy et al., 2013). 
Recent advances in MRI technology utilizing anatomical (T1- and T2-weighted imaging) along 
with functional (diffusion-weighted imaging, dynamic contrast-enhanced and spectroscopic 
imaging) sequences resulted in improved diagnostic accuracy of prostate cancer. (Lawrentschuk 
& Fleshner, 2009; J. Thompson et al., 2013). This multi-parametric MRI (mpMRI) approach is 
still in the development phase and its interpretation can vary depending on the type of software 
and MRI machine being used as well as the experience of the radiologist. To date, the most 
advanced MRI imaging technique is 3-Tesla MRI which offers high spatial resolution and soft 
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tissue contrast (Pedler, Kitzing, et al., 2015).. MRI still can’t replace histology which is regarded 
as the gold standard approach for the diagnosis of prostate lesions.  
2.3.Histology 
 
The most reliable technique to diagnose prostate gland lesions is histopathology which involves 
taking a biopsy from the prostate gland. A biopsy gun with a hollow-core needle guided by a 
grayscale TRUS is often used to take multiple cylindrical core biopsies (8-12 usually). The biopsy 
needle and the ultrasound probe are inserted into the rectum. The needle punctures through the 
rectal wall to reach the prostate for sampling while it is being viewed via ultrasound (Mitterberger 
et al., 2010).  
Once a diagnosis of prostate cancer is confirmed through histological examination, the lesion in 
the prepared tissue is graded to determine cancer aggressiveness. 
The most common histological grading scheme for prostate carcinoma is the Gleason’s grading 
system in which affected areas within the prostate are assigned a score from 1-5, with 5 being least 
differentiated (cells appearing immature, not distinguishable as the cells of the tissue it arose from). 
The scores of the two largest cancerous areas identified from histology are combined to determine 
the final score for the cancerous lesion, which ranges from 2 to 10.  A tumor with a score of 2 is 
considered least aggressive while a malignant tumor receiving a score of 10 is considered as most 
aggressive. Tumors receiving a score of 6 or less are considered low grade while 7 is considered 
intermediate grade and 8, 9 and 10 are considered high grade.  (Epstein et al., 2015; Zeller et al., 
2007). 
Prostate cancer can spread to distant organs such as the lymph nodes, liver, lung, bones and brain, 
which can be examined using imaging techniques such as multiparametric 3T-MRI, CT scan, and 
PET imaging.   
Although histological biopsies are invaluable in achieving an accurate diagnosis, they are 
occasionally associated with post-biopsy complications such as infection, bleeding,  pain in 
hypogastrium, perineum or urethra, high body temperature, nausea, vomiting, and the need for 
bladder catheterization (Eichler et al., 2006; Madej et al., 2012). Though quite uncommon, 
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physical alteration such as shearing effect as well as the biochemical effect due to fixation, 
embedding and staining necessary in histology can potentially hinder a correct diagnosis (Li et al., 
2017; Troiano et al., 2009). Usually, a small section of tissue is used in the histological examination 
so there is a possibility of missing the lesion of interest. 
2.4.Synchrotron-based Imaging 
 
A synchrotron is a cyclic electrodynamic particle accelerator, which uses changing 
electromagnetic fields to accelerate charged particles (electrons) to a speed close to the speed of 
light. The electrons are accelerated in a large circular vacuum path containing radiofrequency 
cavities which allow them to acquire more energy and speed.  The larger the vacuum path and the 
more frequent radiofrequency cavities there are, the faster the electron acceleration can be. Once 
electrons achieve the desired speed, the electron beam is passed through a bending magnet or 
insertion device, the latter are also known as undulators and wigglers. These alter the course of the 
electron beam causing the release of a highly brilliant and focused radiation with a wide 
wavelength spectrum ranging from far infrared to hard X-ray. The radiation beam is later directed 
down a beamline working station known as a hutch where different types of samples can be 
exposed (Mobilio et al., 2015). Synchrotron radiation has wide research applications in multiple 
disciplines including, but not limited to, biosciences, environmental sciences, minerals 
exploration, medical research, agriculture, engineering, and forensics.   
 
The advantage of synchrotron radiation is that the X-ray radiation generated has higher intensity 
and brilliance, smaller source size, higher collimation, broader energy spectrum with tunability, 
and higher polarization compared to conventional X-ray. Brilliance refers to the concentration of 
the photons in a beam. The higher the brilliance, the more these photons can hit an exposed sample 
in a unit of time which allows for a more detailed examination of that sample. The better-
collimated nature of synchrotron radiation refers to its more parallel and focused beam compared 
to conventional radiation which minimizes ray dispersion especially when the beam travels for a 
long distance.  Synchrotron radiation is a wide mixture of different rays, each with a different 
wavelength, ranging from far infrared to hard X-ray. Each of these rays can be used alone or with 
others to study an exposed sample depending on interest and sample characteristics. 
Monochromators are commonly used to filter out unwanted rays, which allow the synchrotron user 
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to utilize a ray with a specific wavelength to study a particular sample of interest (Shenoy, 2003; 
Terasawa & Kihara, 1996). 
 
Canadian Light Source: 
The Canadian Light Source (CLS) is housed at the University of Saskatchewan in Saskatoon and 
is the only synchrotron facility in Canada.  It is a third-generation synchrotron facility equipped 
with a 2.9 GeV storage ring (Bisby & Maitland, 2005; Hallin et al., 2006). The facility opened its 
doors in 2004 allowing more than 3000 scientists from Canada and the world to use its synchrotron 
beam for a wide variety of research projects.  
Electrons are produced by an electron gun after it is heated to about 1,000 °C in the presence of a 
very high voltage (~ 200,000 volts). The electron gun is made up of a tungsten-oxide disk 
(cathode). Electrons are passed to a linear accelerator (LINAC) composed of a series of cavities 
each having a microwave radio frequency field of 2,856 MHz. These accelerate electrons to a 
speed close to the speed of light and later inject them into the booster ring. The booster ring is a 
103 m long vacuum cylinder containing radiofrequency cavities in which electrons revolve around 
1.5 million times within 0.6 seconds to achieve an energy of 2900 MeV making them even faster 
(Silzer et al., 2004; Grochulski et al., 2017). Electrons are then passed to an outer vacuum ring 
known as the storage ring which is 170.88 m long with a maximum current of 220 mA. It is 
composed of 24 alternating straight and curved segments. Two dipole magnets (bending magnets) 
make up each curved section which maintains the circular movement of electrons through the 
storage ring. Once electrons pass in between these two dipole magnets, a radiation beam is allowed 
to exit the storage ring tangentially through a photon port and down a beamline hutch where a 
sample of interest is exposed. The beamline has three different compartments; the first one is an 
optic hutch, which has different focusing mirrors and a filtering monochromator allowing for the 
selection of a desired wavelength of the light. The second hutch is known as the experimental 
hutch in which a sample is placed and exposed. The last hutch is a working station from where the 
beam line is operated, and the data is recorded. Within the CLS there are a total of 20 beamlines 
radiated out of the storage ring, and each can be used to expose samples for various research 
applications.  Of these 20 beamlines, eight are devoted to biological studies, of which the 
Biomedical Imaging and Therapy (BMIT) facility was used to image our prostate samples. This 
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unit is generally used for the imaging and therapy of the biological matter (Silzer et al., 2004; 
Grochulski et al., 2017). 
The BMIT facility within the CLS receives two beamlines, the first is from a bending magnet and 
is referred to as “BMIT-BM 05B1-1” or simply “BMIT-BM” and the second originates from an 
insertion device, i.e., multi-pole superconducting 4.3 T wiggler and is referred to as “BMIT-ID 
05ID-2” or simply “BMIT-ID”. The main difference between these two beamlines is the energy 
range of the X-rays they produce. The BMIT-ID 05ID-2 beamline has an energy range of 25 - 150 
keV while the energy range of BMIT-BM 05B1-1 is only 20 – 40 keV. The maximum penetrable 
thickness of the BMIT-BM 05B1-1 beam is 10 cm which is suitable for imaging small breed dogs 
or puppies, cats and tissue samples and was therefore used in our study. The total length of the 
BMIT-BM) 05B1-1 beamline is 26 m and an exposed sample is often placed in a spot which is 
approximately 23 m distant from the radiation source. The beam size at this spot is 240 mm x 7 
mm. This beamline is a multi-modality synchrotron imaging facility which can be used for  
conventional absorption imaging, K-edge Subtraction Imaging (KES), Computer Tomography 
(CT) and In-line Phase Contrast Computerized Tomography (PC-CT) (Grochulski et al., 2017; 
Wiebe et al., 2015). 
 
Phase-contrast imaging: 
Since the discovery of the X-ray by Roentgen more than 120 years ago, there has been continuous 
development and improvement in clinical imaging techniques - the majority of which utilize an 
absorption-based imaging approach. Imaged samples or tissues have unique X-ray absorption 
properties and, therefore, allow different amounts of X-ray to pass through them to a special 
detector providing a shadow of their image.   Tissues with weak or similar absorption properties, 
such as most soft tissues, cannot be differentiated easily through absorption-based imaging. 
(Chapman et al., 1997; Jia et al., 2012) and there was a need for a different kind of imaging 
technique which is not solely based on the absorption imaging technique.  The phase-based 
imaging technique came into being around late 1990 which was based on the contrast generated 
by the phase shift that occurs between different parts of a sample as the X-ray pass through it. This 
phase-based imaging is more sensitive to the density difference even though that difference is very 
small, making it more useful and more informative in imaging soft tissue as compared to the 
17 
 
absorption-based imaging (Chapman et al., 1997). The phase contrast of soft tissue is due to the d 
(decrement of the real part of the complex refractive index (n) of the tissue) and the phase shift 
(change in phase angle of a waveform) of the X-ray that happens when the rays transmit through 
the tissue (Figure 2.4). The noticeable soft tissue contrast by the phase-based imaging is due to the 
fact that the d for many biological tissues is 1000 times larger than the absorption contrast 
determining factor (𝛽) of the tissue (Jia et al., 2012).  
 
There are various types of phase-based imaging techniques such as analyzer-based Diffraction 
Enhanced Imaging (DEI), propagation-based in-line propagation phase-contrast imaging (PC-CT), 
and grating-based imaging called grating interferometry. Each of them has its own advantages and 
drawbacks. But the differences are mainly about the complexity of the setup, beam characteristic 
requirements, field of view and finally the quality of phase information that will be retrieved (Pagot 
et al., 2005b). The grating interferometry is usually considered highly demanding for optical 
stability and due to its experimental complexity, it is not available in every synchrotron facility. 
Compared with the DEI, PC-CT is simple in terms of setup. 
 
Figure 2.4. Schematic diagram showing the change in phase shift (Φ0- Φ), attenuation of the 
amplitude (|E|0 - |E|) and the change in propagation direction (α) when the X-rays transmitted 
through the material having the refractive index n (Dhakal Subash, 2019). 
 
Though DEI has been found to give similar image quality and sometimes even higher image 
quality compared to PC-CT while imaging breast tumors and phantoms (Fulvia Arfelli et al., 2000; 
Pagot et al., 2005b; Pisano et al., 2000), and is able to render the phase information more 
sensitively from tissues with low variation in phase (Pagot et al., 2005b), requirements for perfect 
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crystals make it difficult to transform the technique to clinical use (Olivo et al., 2009). On the other 
hand, PC-CT, due to its simplicity and relatively low equipment cost, possesses an excellent 
probability to be adapted for clinical use. It also gives better spatial resolution in the image as it 
enhances the high spatial frequencies, although it requires a high spatial coherence of beam which 
is not a requirement for DEI. Additionally, PC-CT avoids the chance of image quality being 
degraded typically seen with DEI when the beam passes through the analyzer crystal (Pagot et al., 
2005b). 
The setup of PC-CT is almost the same as conventional absorption-based imaging except for the 
space that is allowed to be in between the sample and detector. This distance allows the phase-
shifted beam to interfere with the original beam after being transmitted through the sample while 
it propagates between the sample and detector. The wavefront perturbations thus produced due to 
this phase effect produces measurable Fresnel fringes (Figure 2.5). These fringes are actually the 
edge enhancement of the structures inside the imaged object giving the contrast between the 
structures (Elfarnawany et al., 2017; Olivo et al., 2009). The intensity of fringe increases and also 
gets broader as the distance between the sample and the detector is increased as shown in figure 
2.5. But the primary requirement for the formation of this Fresnel fringe in PC-CT is that the source 
should generate high lateral spatial coherent X-rays. This is usually achieved in a synchrotron 
source by the long source (storage ring) to sample distance and/or with the help of focusing optics. 
 
 
Figure 2.5 Diagram showing the formation of a more prominent fresnel fringe as the detector is 
moved far away from the sample in the PC-CT setup (Dhakal Subash, 2019). 
 
When the sample is thick, the superimposed projection images of the different structures of the 
sample will make interpretation of the image more complicated. So, a computed tomography scan 
19 
 
(CT scan) technique can be applied. This technique utilizes a large number of projection 
radiographic images to produce the cross-sectional tomographic images which enable the 
visualization of the internal structure layer by layer without actually cutting the sample open. Since 
this development in 1967, clinical CT scan technology relies on conventional absorption-based 
imaging. But CT scan technology is not limited only there. Almost every imaging modality in a 
synchrotron facility can utilize the CT technology for the better extraction of the 3D information 
of samples. In PC-CT, a large number of projection images collected at an equal interval between 
180° are merged with the help of specialized reconstruction algorithms to form tomographic 
images preserving the soft tissue contrast (Goldman, 2007; Pagot et al., 2005a).  
 
Very few synchrotron imaging studies have been conducted with prostate glands. A group at the 
University of Saskatchewan conducted a study imaging excised prostate tissue from 20 dogs with 
eight normal prostates, eight BPH and four prostate cancer (Barboza et al., 2012; J. Montgomery 
et al., 2013). The imaging was done at the BMIT-BM beamline of CLS Canada. All samples were 
imaged with US, 16 slice CT, 3T MRI, synchrotron PC-CT, and finally, histopathology was done. 
US and conventional CT gave fewer structural details and it was almost impossible to distinguish 
normal with the pathological cases. In the case of MRI, better soft-tissue contrast was noticed, and 
this was in agreement with the histological findings. There was still insufficient information to 
distinguish different pathological conditions like BPH and prostate carcinoma. However, PC-CT 
was giving better soft-tissue contrast making larger microscopic details like urothelial lining, 
ducts, and acini, adipose tissue, muscular structure, fibromuscular stroma, etc. noticeable in the 
prostate (Barboza et al., 2012; J. Montgomery et al., 2013). Though the details in PC-CT images 
were not as clear as in histological images, the findings clearly indicate that this imaging technique 
is a potentially promising diagnostic tool in the future. There is a need for more studies to replicate 
and quantify the result and even to improve the quality of imaging. 
 
Pagot et al. (2005b) had performed in-line propagation-based phase-contrast imaging of a phantom 
simulating breast tissue in which they imaged a 1mm tumor-like mass inserted in 4.2 cm thick 
wax. The X-ray energy that was used was 18 keV and the detector had an effective pixel size of 
7.5 *7.5 um2. PC-CT was found to give the highest edge visibility for the largest sample to detector 
distance (SDD) i.e. 8.8 m vs 0.3 m, 1 m, and 4.5 meters. Also, the granular texture related to the 
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density variation within the structure was visible in an image from a large SDD setup, which was 
not visible in images from a small SDD setup, though the quantitative contrast was not much 
different among them. Research conducted at the BMIT-BM beam-line at the CLS (Izadifar et al., 
2017a) to determine the effect of propagation distance on the image quality from PC-CT used 
25keV X-ray energy and three different propagation distances of 22cm, 76cm and 147cm in 
accessing hydrogel cardiac patches. They noticed that the edge sharpness was highest with the 
largest SDD. (Nesterets et al., 2015) conducted a study in which they had imaged a polycarbonate 
phantom (simulating breast tissue characteristics) of 10 cm diameter with three different X-ray 
energies (38  keV, 45 keV, and 50 keV) using a Hamamatsu CMOS flat panel detector having a 
pixel size of 100 *100 um2. Having the fixed source to detector distance of 142.5 m, they had 
imaged the phantom altering the SDD to four different values (27cm, 1m, 2m, and 5m). From this 
study also, it was noticed that the edge sharpness was lowest and was blurred in the smallest SDD 
i.e. 27cm, while the increase in SDD was giving better phase-contrast fringe and thus edge 
sharpness, as well as the contrast to noise ratio (CNR) and figure of merits (FOM). The SDD of 
5m had given the best phase information ((Nesterets et al., 2015) 
 
All of these above studies with differing SDD values found that the largest SDDs were giving 
better images in every case. But one study using the table-top micro-CT system for propagation-
based phase-contrast imaging of insects and a thin plastic sheet using a micro-focus source and 
CCD detector (pixel size of 24mm) found that the increase in the SDD initially increased the phase 
contrast and after a certain point, the image quality degraded. Here the increased propagation 
distance enhanced the phase information but eventually, penumbral blurring started appearing 
producing a low-quality image (Gui et al., 2012).  Penumbral blurring is blurring of the edge of 
the object in an image due to the non-perfect source/focal spot (not being a point source) and is 
usually exacerbated by a long sample to detector distance. The formula to calculate the size of 
penumbral blurring is given as follows: [source size or focal spot * R2/R1], where R1 is the source 
to sample distance and R2 is SDD. The blurring increases as the R2 is increased. Theory indicates 
that to prevent the blurring that causes the image quality to deteriorate, the SDD should be within 
the range for which the penumbral blurring can fit in one pixel of the selected detector. To allow 
the larger SDD, we can choose a detector with larger pixel size, but again increasing the pixel size 
of the detector will lower the resolution (GOROVIKOV Sergey, personal comm., January 16, 
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2018). In the above-mentioned synchrotron PC-CT related studies, they had never tried the SDD 
beyond the limit of penumbral blurring.  
 
In the previously discussed (Nesterets et al., 2015) study, the CNR was decreasing with the 
increase in keV but another quality index, the signal to noise ratio (SNR) was found to be optimal 
at the X-ray energy of 45keV for most of the material tested. Another study done by Olivo et al. 
(2009) had used 15, 17, 18, and 30 keV energy X-rays for imaging post-mortem samples of breast 
tissue with an almost uniform thickness of 2 cm. They had found that the details in the image were 
clearer when imaged with the 18 keV compared to 17 keV, demonstrating that the higher energy 
radiation gives greater details. But at the same time, they also found that the image quality 
degraded when it was imaged with 30 keV. These findings clearly indicate that there is an optimal 
point for energy. It was also discovered that the quality imaging of the geometric object with a 
sharp edge is still possible with high energy, which is otherwise not suitable for imaging a complete 
biological object with a gradual change in the refractive indices of the structures within it.  
 
Another important factor that needs to be considered before implementing an imaging technique 
for clinical use is the dose imparted while imaging. If PC-CT is depositing a harmful amount of 
radiation while imaging, then it is not useful beyond ex-vivo imaging. Some studies have also been 
conducted to determine the clinical feasibility of PC-CT and ways to reduce the dose imparted. 
One way to reduce the radiation dose is by reducing the number of projections. Normally, it is 
considered that the number of projections (N) required is determined by N∼πD/ (2P) in PC-CT 
with the FBP algorithm of reconstruction (where D is the thickness of the sample and P the detector 
pixel size) (Zhao et al., 2012). Studies have been conducted to investigate the possibility of a lower 
projection number without compromising the quality of images. In the Izadifar et al. (2017) study 
discussed above, projections were separately collected throughout a 180-degree rotation with four 
different rotation increments giving total projections of 3000 (standard), 1500, 1000 and 750. They 
observed that the anatomical features in tomographic images were well visualized even in the 
images from low projection numbers, i.e. 1500, but it was difficult to identify the microstructures 
with 1000 and 750 projections. The dose imparted while imaging with 1500 projections was within 
the range of the dose imparted by a commercially available micro-CT scanner. 
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Another way to image with a low dose of radiation is to decrease exposure time for each projection. 
But at the same time, the low exposure time may cause a low signal to noise ratio and thus low 
image quality of each projection and the resulting tomographic images. This is because the flux of 
the synchrotron is usually fixed, so the number of photons hitting the sample cannot be increased 
to compensate for the loss due to the short exposure time. This makes the sparse view technique a 
preferred one to achieve the goal of reduced radiation rather than reducing the exposure time per 
projection. But analytical algorithms such as the standard FBP algorithm, used for CT 
reconstruction will cause serious aliasing artifacts such as streaks to appear in the image when 
used to reconstruct an incomplete number of projections (Barrett & Keat, 2004; Melli et al., 2016). 
There is also the possibility of reducing the radiation dose farther by increasing the keV of the 
radiation source, but the challenge is that optimal value of keV should be determined so that the 
high keV won’t cause at the same time, a reduction in phase contrast (F. Arfelli et al., 1998; 
Burattini et al., 1995; Zhao et al., 2012). 
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3. Hypothesis and Objectives 
 
Our general hypothesis was that PC-CT will be closer-to-histology than US and MRI in the terms 
of having the power of detecting different structural features and small pathological lesions within 
the prostate. This study had four objectives: 
• To examine the ability of synchrotron-based in-line propagation phase-contrast 
computerized tomography (PC-CT) to characterize and differentiate various structural 
features and pathological lesions within human prostatic tissue samples in comparison to 
US, MRI, and histology.  
• To evaluate the usefulness of a sparse view image reconstruction technique 
(reconstruction with 50% and 25% of the total number of the projections) to determine if 
similar quality images can be obtained compared to reconstructions using 100 % of the 
projections. 
• To quantify the radiation dose received by the patient (canine cadavers) during PC-CT 
imaging and to analyze the corresponding dose with a sparse view technique. The goal 
was to reduce the radiation to the patient during PC-CT imaging. 
• To develop a human positioning device for PC-CT imaging of human prostate in situ.  
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4. Materials and Methods 
 
4.1.TURP sample processing 
 
The prostate tissue samples were from patients who underwent TURP due to BPH or suspected 
BPH at the Royal University Hospital (RUH), University of Saskatchewan. Samples were de-
identified as to patient identification and medical history and the use of human samples was 
approved by the University of Saskatchewan Biomedical Research Ethics Board (Bio-REB). 
TURP is a standard surgical procedure in BPH management where the hyperplastic growth of the 
prostate from the area surrounding the prostatic urethra is scraped out and the area electro-
cauterized. Resect-scope, which is an instrument containing a camera with a surgical instrument, 
is used for this purpose which will be inserted through the penis to reach up to the enlarged 
prostate. Although the patients were treated for BPH, clinical diagnosis for those excised TURP 
tissues from the patients were never received. TURP samples were used for this study as they were 
readily available, and biopsy samples of the prostate and whole human prostates were not 
available. The provided TURP samples (each with ~1 cm length, ~0.5 cm width, and ~0.3 cm 
thickness) were already fixed with 10% buffered formalin immediately after surgery. The tissues 
were stored in the formalin for varying period of length ranging from months to a year in between 
surgery and the experiments. The samples were taken out of the formalin and embedded into clear 
gelatin within x-ray lucent polypropylene plastic jars (Nalgene snap-cap vials of 3.3 cm (91.5ml), 
4.5 cm (141.5ml), and 4.8 cm (179.1ml)  diameters with same thickness of 1mm, Nalge Nunc 
International, New York, USA), (Figure 4.1; Table 4.1) for imaging. The jars used were already 
proven to be radio-transparent from a previous experiment conducted by our team.  The gelatin 
embedding was done to provide the TURPs specific orientation, immobilize them while imaging, 
enable imaging of the same TURPs by other imaging modalities in the same orientation and to 
allow for slicing of histological samples in the same plane as the imaging. Gelatin was used as it 
is transparent for x-rays, ultrasound imaging, and MRI. The gelatin used was unflavored, clear 
Knox® gelatin (Smith® Foods, Ltd, Winona, ON Canada). To embed the tissue samples from 
each patient in gelatin blocks, the gelatin was prepared as follow; one pouch (7.2 gm) of gelatin 
was poured over 50 ml of cold water and stirred well. After that, 50 ml of boiling water was added 
and stirred until all the gelatin granules were completely dissolved. Once the solution became froth 
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less, the warm solution was added to fill one-half of the plastic jar (i.e. ~40 to 50 ml). Once that 
gelatin solidified at room temperature in around half an hour, TURP tissues typically three in a 
layer, were placed over the solidified gelatin in the jar. Additional warm (~50 to 55 degrees 
Celsius) gelatin was poured over to cover the tissues and allowed to solidify again at room 
temperature. Lead arrow markers were placed on the outer surface of the jar to indicate the tissue 
location for synchrotron imaging as shown in Figure 4.1. The jars were stored at refrigeration 
temperature for varying time ranging from two weeks to 11 months waiting for imaging shifts at 
CLS. 
 
Figure 4.1 Jars of samples with lead arrow markers (white filled arrows: upper lead markers, red 
filled arrow: lower lead marker) indicating tissue locations (solid black arrows). 
Table 4.1 Diameter of the sample jars used for imaging. 
Samples imaged Diameter of Jar 
T2 3.3 cm 
T9-18894 4.5 cm 
T13 4.8cm 
T14 4.8 cm 
T1755K15248 3.3 cm 
T1 3.3 cm 
T7 3.3 cm 
T3-14sph 3.3 cm 
T9-18660 3.3 cm 
T6 3.3 cm 
T15-sph-18340 3.3 cm 
T1a 3.3 cm 
T7a 3.3 cm 
T3a 3.3 cm 
T9a 3.3 cm 
T6a 3.3 cm 
Tt15a 3.3 cm 
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4.2.Inline propagation PC-CT imaging and image reconstruction procedures 
 
Two imaging shifts were carried out at the CLS on March 22, 2018 and February 1, 2019. The 
samples (Table 4.1) were all imaged with the setup in the BMIT–BM hutch as shown in Tables 
4.2 and Figures 4.2 and 4.3.  
Table 4.2 PC-CT Imaging setup used in our study. 
Parameter Value Reason for choosing 
keV 25 Determined by beamline 
scientist based on the radiation 
transmitted through the sample 
and pixel saturation values 
 
Beam type Filtered whitebeam (Tin 0.5 
mm, Aluminium 4.5 mm) 
 
Greater number of photons 
Detector Hamamatsu Orcha flash 
AA60 detector, (13.6 um2 
pixel size) with Luac 
scintillator. 
 
Small pixel size and fast 
readout speed. 
Sample to 
Detector 
Distance 
(SDD) 
1.5 meter Wanted to have 1.85 m to 
maximize phase information 
without penumbral blurring but 
as the structural limitation of 
out BMIT hutch stage which 
only allows us to choose SDD 
either between 0 to 1.5 m or 4.5 
m to 6 m. 
 
Mode Step and shoot Previous experience 
 
Projection # 2250 Minimum projection numbers 
suggested for this setup. Higher 
than this value also does not 
give any beneficial results. 
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Figure 4.2 BMIT-BM imaging hutch including sample stage (solid black arrow). Black outline 
allow indicates an inlet window for radiation beam into the hutch. 
 
Figure 4.3 Sample jar (containing a whole canine prostate indicated by black outline arrow) on 
the imaging stage (solid black arrow) in the BMIT-BM hutch, representing our imaging setup 
except for the type of sample used.  
Due to the small height of the beam used (3.1 mm), the whole area of a sample couldn’t be imaged 
at one time. So each 3.1 mm high view was imaged beginning from just below the tip of the upper 
lead arrow marker (top of TURP samples) and successive views were collected by moving the 
stage up 3 mm following each view (with a 0.1 mm overlap of the views) until the tip of the lower 
lead arrow marker (bottom of sample) was reached. The imaging procedure was controlled from 
the control room just beside the imaging BM hutch using HiPic 9.3 pf7 software from Hamamatsu 
Photonics (Shizuoka, Japan). 
At the beginning and end of imaging, each view 20 dark images (without the beam) and 20 flat 
images (without sample) were also collected. These were later used to make corrections to the 
collected tomographic projections prior to reconstruction by subtracting both dark projections and 
flat projections from original tomographic projections (Wolkowski et al., 2015). 
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 The collected cross-sectional tomography slices were reconstructed into a PC-CT image using a 
parallel beam geometry filtered back projection (FBP) algorithm using the Linux-based open-
source software UFO-KIT with the help of in-house graphic user interface (GUI) developed for 
use by BMIT users was used.  
It is the primary software that BMIT uses for fast reconstruction of CT data.. The following settings 
were used: regularization value 2.5, filter strength 3 and auto axis of rotation. 
4.3.MRI imaging 
 
Imaging of all samples (Table 4.1) was performed at the Western College of Veterinary Medicine 
on February 11 - 13, 2019.  The lead markers on the sample jars were replaced with vitamin E pills 
as they are visible in the MRI image and metal cannot be used during MRI imaging (Figure 4.4). 
The MRI machine used in the WCVM was a MAGNETOM Symphony 1.5T machine (wrist array 
coil; SIEMENS, Munich, Germany). T1-weighted images were collected with following 
parameters: FOV (field of view) = 70mm, SLT (slice thickness) = 1.3mm, TR (repetition time) = 
925ms, TE (echo time) = 115ms, Flip angle = 180 degrees, Matrix = 164x256, Voxel size = 
0.3X0.3X1.3mm³, Bandwidth = 150Hz/Px and Turbo factor = 17 while T2-weighted images were 
collected with FOV = 70mm, SLT = 1.3mm, TR = 685ms, TE = 14ms, Flip angle = 90 degrees, 
Matrix = 164x256, Voxel size = 0.3X0.3X1.3mm³, Bandwidth=130Hz/Px, Turbo factor=17. T1 
and T2-weighted MRI images were collected in the same plane as the PC-CT images (Figure 4.5).   
 
Figure 4.4 Sample jars with vitamin E pills taped on them as MRI markers. 
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Figure 4.5 Sample jar (indicated by the red arrow) being MR imaged. 
 
 
4.4.US-Biomicroscope Imaging 
 
The most commonly used clinical ultrasound machine operates with frequency in a range of 2 to 
12 MHz. As the frequency becomes higher, the resolution increases simultaneously with reduction 
of the penetration depth. A Vevo® 3100 Ultrasound Biomicroscope (FUJIFILM VisualSonics, 
Toronto, Canada) in the Department of Veterinary Biomedical Sciences at the WCVM was used. 
It is a state-of-the-art ultrasound machine with a probe frequency ranging from 15 to 71 MHz. The 
depth of penetration is limited, so it is only suitable for imaging tissue samples or smaller 
laboratory animals such as rats and mice, and not for clinical purposes. For US-Biomicroscopy, 
the TURP samples still embedded within the gelatin blocks had to be taken out of the plastic jars 
as the plastic is not transparent for the ultrasound. This was done without disrupting the smooth 
cylindrical structure of the gelatin blocks by gently inserting a long fine round aluminium stick 
from a point at periphery between gelatin block and plastic jar and moving it throughout the 
periphery of the block to loosen the block form the jar. Gentle multiple tapping from the bottom 
while the jar was in an inverted position caused the gelatin block to come out from the jar. From a 
test trial with a sample, it was found that the MX400 linear transducer (30 MHz frequency, axial 
resolution 50 μm, depth of penetration 20 mm, and width coverage of 15.36 mm) was suitable for 
our samples considering the maximum possible resolution versus the maximum depth of 
penetration that could be achieved while imaging the gelatin cylinder in cross-section. The excess 
gelatin along the longitudinal side of the cylinder was removed as much as possible by cutting 
with microtome blades (Feather Safety Razor Co., Ltd Osaka, Japan) to reduce the cross-sectional 
30 
 
diameter for imaging while still keeping the TURP samples immobilized in the same position and 
to allow the gelatin block to be subsequently returned to the jar in its original orientation (Figure 
4.6). The depth and width coverage capacity of the transducer was still not enough to cover the 
resulting sample diameter so each cylinder was imaged in two steps: left and right, (starting from 
top to bottom each time) to cover the whole width and again by inverting the cylinder and imaging 
from the opposite side (again left and right separately) to cover the remaining depth.  
 
Figure 4.6 TURP samples (solid black arrows) within longitudinally trimmed gelatin block to 
reduce the imaging depth. Black outline arrows indicate trimmed surfaces. 
 
A water trough with a wax block at the bottom was filled with water the day before imaging to 
allow the air bubbles to come out of the water. On the imaging days (February 15 -22, 2019), the 
sample was kept immobile by pinning a needle through the sample cylinder into the wax block 
(Figure 4.7). The average gain value of 24 dB, three focal points setting at the 8 mm, 10 mm and 
12 mm of depth and the step size of 0.04 mm were set constant for all the B-mode sample imaging. 
The probe tip was submerged in water just above the surface of the sample cylinder and was set to 
move along the longitudinal axis of the gelatin block while moving along a straight rail to capture 
the cross-sectional images comparable (in the same plane) as the PC-CT and MRI images.  
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Figure 4.7 US transducer (black arrow) hanging on rail and sample block (green arrow) fixed in 
place underwater (red arrow). The transducer in the picture is perpendicular to the orientation we 
had used in our sample imaging. This picture was taken before we had decided the imaging 
protocol.  
 
After ultrasound imaging was completed, all the sample blocks were placed back into their 
respective jars without disturbing the orientation and position of the embedded TURP samples. 
The resulting space between the samples and the jar (as the gelatin cylinders had been trimmed for 
US imaging) were refilled with liquid gelatin and allowed to solidify at room temperature for 
around 30 minutes. This was to preserve the firm cylindrical straight structure of the sample block 
in its original orientation so that the tissues could be subsequently sliced for histology in the same 
plane as the already captured images from the different imaging modalities. After the gelatin 
solidified, all samples were refrigerated (2-8 degree Celsius) until histological processing was 
carried out (i.e. for next two and half months).  
4.5.Preparation of histology slides and their selection for comparison 
 
Detailed procedures of histological preparation of the tissues are described in Appendix 1. 
Once the histology slides were prepared representative slides were selected making sure TURP 
samples were not missed nor repeated. As each sliced tissue layer (see Appendix 1) shouldn’t be 
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less than 3 mm in thickness it was decided to randomly choose one slide among the slides made 
from each 3 mm slice. Once the slide from any given slice was chosen, the flexibility to move a 
maximum of 2 slides above or below the chosen slide was allowed if the histological preparation 
of the selected slide was poor or only had a small amount of tissue compared to the adjacent slides. 
After that, the selected histology images were matched with the sequential PC-CT images to ensure 
that one slide for each tissue without repetition were taken. In a few cases, a unique TURP sample 
was not included in any of the histology slides selected. So, the corresponding histology slides 
were found and added to the list of slides to be compared. In this way, 22 histology slides were 
selected from 13 patient samples which in total included 61 TURP tissues. A high-resolution 
digital copy was made for each of the selected slides.  
Matched images to the histology slides were selected from each imaging modality and 
comparisons were performed at the same magnification. The PC-CT images were set to 100% 
magnification as the reference magnification and the same physical magnification was applied for 
other modalities. This resulted in a magnification level of 11% magnification for the histology 
images. Each image was separately evaluated blind to sample identity. The presence of the 
following structures was evaluated: glandular lobules, dilated acini, smooth muscle, fibrous tissue, 
adipose tissue, blood vessels, lymphatics, mineralization, and inflamed area. These are structures 
that were identified in the 11% magnified histology images when a small pre-study examination 
was conducted with a small practice set of images. If present, their size (longest diameter/length) 
was determined from the images using “straight” tool from ImageJ (Rasband, 2018.) The presence 
and size of all structures were compared among the matched images from the different imaging 
modalities and histology.  
 
Fibrous tissue was evaluated differently than the other structures as it is the basic structure of the 
prostate tissue. Even when none of the structures listed above were detected, fibrous tissue was 
still present. So, it was not possible to mark each and every area containing the fibrous tissue. 
Therefore, it was decided to pick certain locations in images from all modalities and access if those 
are fibrous area or not. The examination was started with the US images as US images were 
assumed to be of lowest quality and should reduce bias in examining the areas in the other 
modalities afterward. It is due to the fact that, because of very bad image quality, we would have 
almost no confidence from US images in saying the encircled area really a fibrous tissue area. Four 
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different locations (~1000um) were identified in each of the US images that appeared to be fibrous 
areas, and the same locations in the corresponding images from the other imaging modalities were 
also identified. Each of the identified structures in the 11% magnified histology, PC-CT and MRI 
images were evaluated independently to estimate whether they were fibrous tissue or not. After 
completing judgement in all modalities, the estimations were cross-checked with the histology 
images. 
4.6.Sparse view image reconstruction and image comparison 
 
For the comparison of the quality of PC-CT images reconstructed from different numbers of 
projections, 37 randomly selected tissues from the original set of 61 tissues were used, keeping at 
least 2 from each patient (because of the time constraint).  Images were already reconstructed with 
100% of the total number of projections (i.e. 2250), so the slices were then reconstructed using 
50% of the total projections (every second projection) and 25% of the total projections (every 
fourth projection) using the same techniques as before. In this way, 111 reconstructed PC-CT 
images (100%, 50%, and 25% total projections) from 37 tissues were gathered and then renamed 
and randomized so that their identity was unknown to the observer. Each of the deidentified images 
was evaluated as before. Following the evaluation, the identity of each image was revealed, and 
they were compared with their corresponding images within the TURP sample (100% vs 50% and 
25% projections) as before.  
4.7.Quantifying the radiation dose received by the patient (dog cadaver) during PC-CT 
imaging at the BMIT-ID beamline. 
 
Prior to this current study, radiation dosimeters and an ionization chamber were utilized to collect 
radiation exposure data during PC-CT imaging of canine cadavers. Five dog cadavers in a separate 
study were imaged in the BMIT-ID beamline using a custom-made aluminum and x-ray friendly 
plastic canine holding device to keep the subject in a vertical position (Figure 4.8). Measuring 
delivered radiation doses was not a goal of this previous study but the data were collected at that 
time to minimize the number of cadavers imaged and provide the raw data for this study. A 120 
KeV filtered whitebeam (filter: 1mm Al, 1.5 mm Cu) and a Dalsa detector (Teledyne DALSA 
Waterloo, Ontario) with a 50um2 pixel size were used. The subject was 55m from the wiggler 
source (3.5T) and the sample to detector distance was 2.0 m. The ionization chamber was placed 
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in the beam between the source and the dog cadaver at 50 m from the source and just after the 
entry point of the beam into the experimental hutch. The beam width at the subject (55m from the 
source) was 110 mm in width and ~7.8 mm in height. Three radiation dosimeters were placed on 
the outside of the canine cadaver-holding device during PC-CT imaging of each cadaver, one at 
the approximate vertical center of the beam and the other two (upper and lower) 50 mm away from 
the central one to measure the scatter of the beam. The approximate vertical centre was determined 
by lasers aligned to the beam. Optically stimulated luminescence (OSL) technology based 
Luxel®+ dosimeters (LANDAUER, Glenwood, USA) were used. They contain a very thin strip 
of AI2 O3:C (aluminum oxide) crystalline material which is a key part in measuring the radiation 
exposure.  
 
Figure 4.8 Three radiation dosimeters (black arrows) attached on the outer surface of the cone 
(red arrow) containing the dog cadaver. The middle one was centered in the horizontal beam, and 
the upper and lower dosimeters were 5 cm away from the center dosimeter 
The cumulative dose reading from the ionization chamber was recorded immediately after the x-
ray exposure. The reading was subsequently corrected for distance as the ionization chamber was 
50 meters and the cadaver was 55 meters from the radiation source. The correction was done by 
multiplying the ionization chamber reading by (50/55) ² = 0.86 (Ning Zhu, BMIT Beamline 
Scientist, personal communication, October 24, 2019). The cumulative radiation dose recorded in 
the luxel+ dosimeter was measured at Landaur’s laboratory (Landauer, Inc., 2 Science Road, 
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Glenwood, Illinois, USA) by stimulating the AI2 O3:C (aluminum oxide) crystalline material of 
the dosimeter by selected frequencies of laser light to cause it to luminesce in proportion to the 
amount of radiation to which it was exposed.  The total time the dosimeter was exposed to radiation 
was calculated by determining the number of projection images in which the central dosimeter was 
visible out of the total 2000 projection images. This included projections where the dosimeter was 
directly exposed to the beam, projections when exposed to the beam at an angle and projections 
when exposed to the beam after it had travelled through the cadaver. The dosimeter would be 
radiated more whenever it was directly exposed to the beam compared to when the beam was 
passing through the dog first and hit the dosimeter afterward. This ratio of visible/total projections 
for each cadaver was used to derive the corresponding doses the dosimeter would read if the 
dosimeter had been exposed for all 2000 projections directly to the beam. The calculated dose was 
then compared with the ionization chamber reading.  
The different luxel+ dosimeters for imaging different dog cadavers were exposed to the direct 
beam for different numbers of projections unlike the standard 2000 projections for the ionization 
chamber. Therefore, to make the dosimeter readings comparable with the ionization chamber 
readings and to establish the relationship between these two, it was necessary to derive the 
corresponding dosimeter exposure if the dosimeters were exposed for all 2000 projections to the 
beam. Moreover, the central dosimeters for Dog 1 and Dog 5 were only indirectly exposed to the 
beam i.e. when facing towards the detector. The rays were passing through the dog's body and then 
only hitting the dosimeters (transmitted exposure).  This non-uniformity from cadaver to cadaver 
was because the starting position of the dosimeters was not the same for imaging each cadaver. 
These two cases were taken to begin further analytical calculations to finally derive the 
corresponding dosimeter exposure if the dosimeters were exposed for all 2000 projections to the 
beam, as discussed in corresponding results section.  
4.8.Designing a holder for PC-CT imaging of a human pelvis 
 
The purpose of this work was to design and test a tool to hold a human pelvis or a pelvic phantom 
for synchrotron PC-CT imaging as a simulation of non-invasive in-situ human prostate imaging. 
Ultimately, if synchrotron-based X-ray imaging allows for earlier detection of prostate cancer it is 
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hoped that it may allow for more focal therapy of prostate cancer in men where the disease often 
only affects a small portion of the prostate gland. 
A previous graduate student had already designed and developed a canine positioning device to 
perform PC-CT prostate imaging of dogs (Figure 4.9). The prostates of several cadavers and six 
live dogs were successfully imaged in-situ using the canine positioning device. This device had an 
aluminum base portion to facilitate attachment to the multi-axis positioning table in the BMIT-ID 
hutch. So, it was decided to design the human-specific device to attach to the aluminum base 
portion of the canine positioning device in place of the plastic cradle that supported the dogs. This 
would take advantage of an already manufactured base where the stability performance was 
already known for that structure. We would be using it as a “pre-base” structure of our holder. 
 
Figure 4.9 Canine positioning device (black arrow) holding a live dog (red arrow) for PC-CT 
imaging in BMIT-ID at Canadian light source 
 
Before starting to design, the basic requirements of the pelvis holder that we were going to build 
had to be determined. These specifications were;  
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• The maximum weight of the holder shouldn’t be more than 55kg (assuming the maximum 
weight of pelvis would be 50 kg, the aluminum base was already around 25kg and the MRT 
stage on BMIT-hutch could only lift up to a total of 130kg.  
• Height of the holder ~45cm. 
• Should be able to hold possible exudates from samples. 
• The maximum acceptable movement of the holder is less than 6.5 um2 as the minimum 
pixel size of the detector we had planned to use was 6.5 um2.  
• The holder’s main part through which radiation would pass should be made up of 
polycarbonate or polyethylene. Other structures should be made up of any light metal like 
aluminum.  
• To make the holder suitable for a smaller as well as a larger pelvis, two polycarbonate or 
polyethylene holders (one with 50 cm diameter and another with 35 cm diameter) had to 
be designed. 
• The maximum thickness of the holder wall should be 0.3 cm to ensure transmission of at 
least 90% of the radiation. 
In collaboration with RMD Engineering Inc. Saskatoon, funded by Mitacs Accelerate, the pelvis 
holder was designed using Autodesk Inventor 2017 software (ADI). An aluminum frame was 
selected for its weight and strength. Ongoing consultations directed various structure and design 
modifications and confirmed the need to use an artificial pelvis. The University of Saskatchewan 
prostate research team advised mimicking a real human pelvis with a male pelvic phantom 
(radiological device) or a pelvic structural model to mimic a real pelvis from a radiological 
perspective (i.e., with the use of animal flesh around a bony pelvis and placing a real prostate at 
the centre). The final selection was a single polyethylene/polypropylene holder of 41.8 cm external 
diameter and 41.2 cm internal diameter, with additional clamps at the lower part of the holder to 
secure it to the aluminium frame. The final design was approved by the prostate research team in 
a meeting. 
4.9.Data collection and analysis 
 
For objective 1 (prostatic structures in different imaging modalities), the experimental design was 
a cross-over design. Based on the structures visible in the 11% magnified histology images, the 
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following structures were analysed and compared among the modalities of detection. Although 
there is no relationship between the presence of the following structures with the occurrence of 
prostate cancer, the ability to identify the following structures is an indicator of image quality 
obtained with the various modalities.  
 
List of different structures and pathological lesions that were recorded. 
Glandular lobules 
Dilated acini (>350um) 
Area of glandular tissue (>1000um) 
Smooth muscle (>1000um) 
Fibrous tissue (>1000um) 
Adipose tissue (>1000um) 
Blood vessels (>150um) 
Lymphatics (>150um) 
area of mineralization 
Inflamed stromal area (>1000um)  
Inflamed glandular area (>1000um) 
 
A total of 646 data points were collected on the above structures. Of those, 91 were visible either 
in PC-CT, MRI or US but not in histology.  These structures were designated as artifacts, 
representing false-positive results, based on the assumption that histology is the gold standard 
reference diagnostic technique for our comparisons. Further, all structures that were found 
misidentified in the 11% magnified histology images (n=18) when compared to the 100% 
magnification histology images were designated as correctly identified structures to make the 11% 
magnified histology an absolute reference diagnostic modality, based on the assumption that the 
ability to accurately identify structures in the 11% magnified histology is the same as in the 100% 
magnified histology.  
 
 
No statistical significance tests were performed on structures with n≤10; these structures did 
receive a descriptive analysis. This included mineralization (n=3), adipose tissue (n=4), smooth 
muscle (9), inflamed stromal area (n=10) and inflamed glandular area (n=6). All other structures 
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were statistically analysed among different imaging modalities with the McNemar χ2 test. As 
histology was assumed to be the gold standard reference diagnostic technique, there was no 
rationale to compare the difference between the histology images and the PC-CT, MRI or US 
images. The histology would always be found significantly more powerful unless both modalities 
compared identified the same number of structures.  Consequently, the McNemar χ2 test was only 
used for comparing PC-CT with MRI, PC-CT with US, or MRI with US.  Two categories of 
structures were created for each imaging modality for the McNemar χ2 test: “agreed with 
histology” and “not agreed with histology”. Since “misidentified structures” and “not visualized 
structures” were both unwanted outcomes from a clinical point of view, they have been placed into 
the “not identified” category. There were also some structures that were present in histology as 
individual structures (let’s say x in number) but with imaging appeared as a combined structure(s) 
(let’s say y in number) at the same location. The x-y number of structures were included in the 
same category “not identified”. Identified individually as in histology (correctly identified) 
structures and the combined structures (y) were included in the “agreed with histology” category. 
The same process was applied for presenting number of structures in Tables 5.2-5.4 as appropriate. 
The McNemar χ2 significance test was applied only if the discordant pairs are more than 25 in 
number.  
 
For size comparisons, three different types of data pairs were compared. The statistical analyses 
used were based on the type of pairs and the nature of the data. Type one: size comparison of the 
structures correctly identified in both histology and a specific imaging modality. For example, a 
comparison of the size of blood vessels correctly identified in histology and PC-CT (Figure 4.9: 
sizes of “a”, “b” and “c” vs sizes of “a’”, “b’” and “c’”). This kind of comparison is the dependent 
sample comparison. Type two (independent samples): histology-measured sizes of structures 
correctly identified in both histology and a specific imaging modality vs sizes of structures that 
were misidentified with imaging (Figure 4.10: sizes of “a”, “b” and “c” vs sizes of “d” and “e”). 
Type three (independent samples): histology-measured sizes of structures correctly identified in 
both histology and a specific imaging modality vs sizes of structures that were not visualized with 
imaging (Figure 4.10: sizes of “a”, “b” and “c” vs sizes of “f” and “g”).  
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Figure 4.10 Schematic diagram representing the three different kind of pairs of data to be 
compared for statistical size comparison. The “ a ”,” b ” and “ c ” in the histology are the 
structures that were also correctly identified in a specific imaging modality represented by “ a’ ”, 
“ b’ ” and “ c’ ” respectively. The “ d ” and “ e ” structures in the histology were mis-identified 
in the specific imaging modality and represented by “ d’ ” and “ e’ ” respectively. The “ f ” and “ 
g ” represent the structures that were not seen at all in the specific imaging modality. The 
structures labeled as prime (a’, b’, etc) refer to the same structures as evaluated with the non-
invasive imaging modalities. 
GraphPad Prism8 software and GraphPad's free web QuickCalc (GraphPad Software Inc., 
California, USA) were used for the statistical analysis. Size comparisons were done by either 
Paired T-test (dependent samples and parametric data), Unpaired T-test (independent samples and 
parametric data), Wilcoxon Signed Rank test (dependent samples and non-parametric data) or 
Mann Whitney U-test (independent samples and non-parametric data). The significance tests were 
applied only if the sample size was at least 3 in each compared group.  
 
For the analysis of the data from the experiment for objective 2 (prostatic structures in different 
sparse view PC-CT imaging), again no statistical significance tests were performed on structures 
with n≤10; these structures did receive a descriptive analysis. This included mineralization (n=2), 
adipose tissue (n=3), smooth muscle (5), inflamed stromal area (n=8) and inflamed glandular area 
(n=2). The McNemar χ2 test was used to compare the PC-CT images reconstructed from different 
numbers of projections – similar to what was done in the Objective 1 data analysis.  The size 
comparison was done between the structures visible in the matched PC-CT images reconstructed 
from two different number of projection images. For example, comparison of cyst sizes measured 
in 100% projection PC-CT and 50% projection PC-CT. The size comparison was done by either 
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Paired T-test (parametric data) or the Wilcoxon Signed-Rank test (non-parametric data). GraphPad 
Prism8 software and GraphPad's free web QuickCalc were used for the statistical analysis as 
before. 
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5. Results 
 
The spatial resolution achieved with the setup and detector used was 12.49 µm.  
5.1.General appearances of different structures in PC-CT 
 
In most of the cases, dilated acini appeared as round or oval structures with a brighter border and 
homogenous dark inner space (Figure 5.1, 5.3 & 5.4). Blood vessels were most of the time seen as 
oval or longitudinal structures with a smooth border. Arterial walls  were found to be brighter  than 
those of the veins. Blood filled vessels were found to have brighter central spaces while empty 
vessels were found to have darker central spaces.  Glandular lobules were found to have a well-
demarcated outline with dark and bright ill-defined small oval structures (regular sized acini) 
bunched together inside the demarcation (Figure 5.1 & 5.4). The glandular areas were also the 
same but did not have well-defined demarcation and were usually smaller in size (Figure 5.1). 
 
                               PC-CT                                             Histology 
Figure 5.1 PC-CT and histology images of matched samples showing glandular lobules, 
glandular area, and dilated acini. 
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Lymphatics were found to have mostly oval or longitudinal but spiked outlines with dark space in 
the middle. Smooth muscles were found to have black and white longitudinal stripes giving the 
appearances of Ganga’s delta of Bangladesh (Figure 5.2).  
 
 
 
 
 
                        
 
                    PC-CT                                                          Histology 
Figure 5.2 PC-CT and histology images of matched samples showing lymphatics and area of 
smooth muscle. 
 
All the visible mineralization appeared as the bright spots or bright glaring headlights (Figure 
5.3).  
 
                          
 
 
 
 
                   
               PC-CT                                                               Histology        
Figure 5.3 PC-CT and histology images of matched samples showing an area of mineralization 
and dilated acini. 
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5.2. Results from the experiment for objective 1: to examine the ability of synchrotron-
based in-line propagation phase-contrast computerized tomography (PC-CT) to 
characterize and differentiate various structural features and pathological lesions within 
human prostatic tissue samples in comparison to US, MRI, and histology. 
 
There were 10 different types of tissue structures identified with histology (Table 5.1). The 
percentage of agreement of these identifications differed among PC-CT, MRI and US (Figure 5.4; 
Table 5.2, 5.3, 5.4). 
Table 5.1 Number of different structures noted in the histology slides of the 61 tissues. 
Structures Count 
Area of adipose tissue 4 
Blood vessel 172 
Dilated acini 125 
Area of glandular tissue 71 
Inflammatory stromal area 10 
Inflammatory glandular area 6 
Lymphatic 118 
Area of mineralization 3 
Glandular lobules 36 
Area of smooth muscle 9 
Grand Total 554 
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           Histology                              PC-CT                              MRI                                  US 
 
                        Histology                      PC-CT                          MRI                             US 
 
                    Histology                            PC-CT                              MRI                              US 
 
 
 
Figure 5.4 Images from different diagnostic modalities of the same plane of the tissues. Black 
oval outline is indicating area of glandular lobule. 
 
In PC-CT, 5.3% (n=8) of structures that were visible individually in histology appeared combined 
into just three structures: three glandular lobules appeared as one glandular lobule; two more 
glandular lobules appeared as one glandular lobule and three glandular areas appeared as one 
glandular area. In MRI, 38.8% of histologically identifiable individual structures (n=19; all dilated 
acini, in 3 tissues out of 61 tissues) appeared combined as just seven structures. In US, 30.8% of 
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histology’s visible unique structures (n=4; all dilated acini, in 1 tissue out of 51 tissues) combined 
to appear as a single structure.  
 
Table 5.2 Structures present and accuracy in identifying them with PC-CT. 
 
Total 
observed with 
histology 
Agreed with 
histology in PC-CT 
(n, %) 
Mis-identified 
in PC-CT (n, 
%) 
Not identified 
in PC-CT (n, 
%) 
Structures 
 
n % n % n % 
Area of adipose tissue 4 0 0 1 25 3 75 
Blood vessel 172 28 16.3 5 2.9 139 80.8 
Dilated acini 125 67 53.6 9 7.2 49 39.2 
Glandular area 71 15 21.1 3 4.2 53 74.7 
Inflamed stromal area 10 0 0 0 0 10 100 
Inflamed glandular area 6 0 0 0 0 6 100 
Lymphatic 118 14 11.9 10 8.5 94 79.6 
Area of mineralization 3 2 66.7 0 0 1 33,.3 
Glandular lobule 36 15 41.7 1 2.8 20 5 
Area of smooth muscle 9 5 55.6 0 0 4 44.4 
Overall 554 146 26.4 29 5.2 379 68.4 
 
With PC-CT, 26.4% of the total structures were identified correctly (Table 5.2). Area of 
mineralization was the most often correctly identified (2 out of 3 areas), followed by smooth 
muscle area (5 out of 9 areas) and dilated acini (67 out of 125 dilated acini). None of the adipose 
tissue areas, inflamed stromal areas, and inflamed glandular areas were correctly identified in 
PC-CT. 
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Table 5.3 Structures present and accuracy in identifying them with MRI. 
 Total 
observed with 
histology 
Agreed with 
histology in MRI 
(n, %) 
Mis-identified 
in MRI (n, %) 
Not identified 
in MRI (n, %) 
Structures 
 
n % n % n % 
Area of adipose tissue 4 0 0 0 0 4 100 
Blood vessel 172 1 0.6 6 3.5 165 95.9 
Dilated acini 125 33 26.4 0 0 92 73.6 
Glandular area 71 0 0 0 0 71 100 
Inflamed stromal area 10 0  0 0 0 10 100 
Inflamed glandular area 6 0 0 0 0 6 100 
Lymphatic 118 3 2.5 0 0 115 97.5 
Area of mineralization 3 0 0 0 0 3 100 
Glandular lobule 36 0 0 0 0 36 100 
Area of smooth muscle 9 0, 0 0, 0 0, 0 0, 0 9 100 
Overall 554 37 6.7 6 1.1 511 92.2 
 
With MRI 6.7% of the total structures were correctly identified (Table 5.3). The most often 
correctly diagnosed structure was dilated acini (33 out of 125 dilated acini). Beside dilated acini, 
only lymphatics (3 out of 118 structures) and blood vessels (1 out of 172 structures) were correctly 
identified. 
Table 5.4 Structures present and accuracy in identifying them with US. 
 Total observed 
with histology 
Agreed with 
histology 
in US (n, %) 
Mis-identified 
in US (n, %) 
Not identified 
in US (n, %) 
Structures 
 
n % n % n % 
Area of adipose tissue 3 0 0 0 0 3 100 
Blood vessel 167 0 0 4 2.4 163 97.6 
Dilated acini 122 10 8.2 0 0 112 91.8 
Glandular area 61 0 0 0 0 61 100 
Inflamed stromal area 2 0 0 0 0 2 100 
Inflamed glandular area 6 0 0 0 0 6 100 
Lymphatic 102 0 0 1 1 101 99 
Area of mineralization 3 0 0 0 0 3 00 
Glandular lobule 34 0 0 0 0 34 100 
Area of smooth muscle 8 0 0 0 0 8 100 
Overall 508* 10 2 5 1 493 97 
* Some missing data for US (n=46) 
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Only 2% of the total structures were identified correctly in US (Table 5.4), and all of them were 
dilated acini.  
Table 5.5 McNemar χ2 tests comparing the abilities of different imaging modalities to correctly 
identify the lesions and structures: 
 Modalities 
compared 
4 Box Values Test 
statistics 
P-
Value 
Result 
Structure 
 
Both modalities+ Modality 1+, 
Modality 2- 
   
 
 
Modality 1 -, 
Modality 2+ 
Both modalities - 
   
Overall 
PC-CT Vs 
MRI 30 116 94.8 <0.05 
PC-CT 
more 
powerful 
 
 
7 401 
   
Overall 
PC-CT Vs 
US 8 134 126.2 <0.05 
PC-CT 
more 
powerful 
 
 
2 364 
   
Overall MRI Vs US 9 28 23.3 <0.05 
MRI more 
powerful 
 
 
1 470 
   
Area of 
fibrous 
tissue 
PC-CT Vs 
MRI 90 39 20.9 <0.05 
PC-CT 
more 
powerful 
 
 
7 68 
   
Area of 
fibrous 
tissue 
PC-CT Vs 
US 89 40 20 <0.05 
PC-CT 
more 
powerful 
 
 
8 67 
   
Area of 
fibrous 
tissue MRI Vs US 94 3 0.16 >0.05 
No 
difference 
 
 
3 104 
   
Dilated 
acini  
PC-CT Vs 
MRI 28 39 24.8 <0.05 
PC-CT 
more 
powerful 
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5 53 
   
Dilated 
acini  
PC-CT Vs 
US 8 59 51.4 <0.05 
PC-CT 
more 
powerful 
 
 
2 53 
   
Dilated 
acini  MRI Vs US 9 24 19.4 <0.05 
MRI more 
powerful 
 
 
1 88 
   
Blood 
vessel 
PC-CT Vs 
MRI 1 27 25 <0.05 
PC-CT 
more 
powerful 
 
 
0 144 
   
Blood 
vessel 
PC-CT Vs 
US 0 28 26 <0.05 
PC-CT 
more 
powerful 
  0 139    
“+” represents the “correctly identified” category and “-” represents the “not-identified” category of 
structures as previously described. 
The use of PC-CT images allowed for the correct identification of 146 (26.4%) structures while 
using MRI and US images only allowed for the correct identification of 37 (6.7%) and 10 (2%) 
structures respectively (Table 5.2-5.4). PC-CT has been statistically proven significantly more 
powerful than MRI and US in enabling the correct identification of structures and areas (<0.05) 
(Table 5.5). 
There was no difference among the size of dilated acini measured from histology, PC-CT, MRI 
and US (p>0.05; Table 5.6). There was also no difference between the histology and PC-CT 
measured sizes for blood vessels, lymphatics, glandular lobules and glandular areas (p>0.05). An 
exception for this pattern was that the size of lymphatics measured from MRI images was bigger 
than the size measured from histology images (p<0.05). We did not have sufficient data for 
statistical comparisons of MRI and histology measured sizes of remaining structures (blood 
vessels, glandular lobule, and glandular area). Similarly, we also did not have sufficient data for 
statistical comparisons of US and histology measured sizes of remaining structures (blood vessels, 
lymphatics, glandular lobule, and glandular area).  
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Dilated acini that were visible in an imaging modality (PC-CT, MRI or US) were found to be larger 
than the dilated acini that were only seen in histology (p<0.05) (Table 5.6). There was the same 
pattern with lymphatics, glandular lobules and glandular areas visible in PC-CT. Blood vessels 
visible in PC-CT and lymphatic visible in MRI were the exception for this pattern, in which no 
difference in the size was noticed (>0.05). For other structures, there was insufficient data from 
those imaging modalities for statistical comparisons. There was also insufficient data to 
statistically compare of other structures (blood vessels, glandular lobule, and glandular area) that 
were visible in histology but not in MRI or US.  
There was no uniform pattern in the relationship between the histology-measured size of structures 
that were correctly identified in PC-CT to those that were misidentified in PC-CT (Table 5.6). 
Sizes of misidentified and correctly identified dilated acini were not found to be significantly 
different (p>0.05). It was the same for glandular areas also. However, misidentified blood vessels 
were found to be larger in size than the correctly identified blood vessels and misidentified 
lymphatics were found to be smaller than the correctly identified lymphatics. For other structures 
(glandular area and glandular lobules) we did not have enough data to statistically compare.
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Table 5.6 Comparison of the size of different structures measured by different imaging modalities. 
Structure Comparison between Sample type Sample 
size 
(former 
and latter) 
Test 
statistics 
P-value 
Result Mean (µm)  
1(former 
/latter) 
SD (µm) 
(former/latte) 
Median (for 
non-
parametric) 
or SEM (for 
parametric) 
(µm) 
(former/latte) 
Dilated 
acini 
Sizes of structures correctly 
identified in both Histology and 
PC-CT 
 
Dependant 
Non-parametric 
67 and 67 Wilcoxon 
S.R. 
0.52 
No difference 698/702.6 346.8/357.8 620/590 
Dilated 
acini  
Histology measured sizes of 
structures correctly identified in 
both Histology and PC-CT Vs 
structures mis-diagnosed in PC-
CT 
Independent 
Non-parametric 
67 and 39 Mann 
Whitney 
0.76 
No difference 698/667.8 346.8/284.3 620/500 
Dilated 
acini  
Histology measured sizes of 
structures correctly identified in 
both Histology and PC-CT Vs 
structures not seen in PC-CT 
Independent 
Non-parametric 
67 and 49 Mann 
Whitney 
<0.0001 
Str. Seen in both 
modalities are bigger 
than not seen in PC-
CT 
698/472.6 346.8/157 620/420 
Dilated 
acini  
Sizes of structures correctly 
identified in both Histology and 
MRI 
Dependant 
Non-parametric 
26 and 26 Wilcoxon 
S.R. 
0.21 
No difference 872.5/835.4 470.3/525 765/635 
Dilated 
acini  
Histology measured sizes of 
structures correctly identified in 
both Histology and MRI Vs 
structures not seen in MRI 
Independent 
Non-parametric 
26 and 80 Mann 
Whitney 
<0.0001 
Str. Seen in both 
modalities are bigger 
than not seen in MRI 
872.5/520.8 470.3/193.2 765/465 
Dilated 
acini  
Sizes of structures correctly 
identified in both Histology and 
US 
Dependant 
Parametric 
9 and 9 Paired- t 
0.16 
No difference 1138/1520 639.1/932.3 213/310.8 
 
1 Former: modality mentioned first in each row of second column. Latter: modality mentioned second in each row of second column. 
52 
 
Dilated 
acini  
Histology measured sizes of 
structures correctly identified in 
both Histology and US Vs 
structures not seen in US 
Independent 
Non-parametric 
9 and 109 Mann 
Whitney 
<0.0001 
Str. Seen in both 
modalities are bigger 
than not seen in US 
1138/566.9 639.1/218.9 870/500 
Dilated 
acini  
Sizes of structures correctly 
identified in both PC-CT and 
MRI 
Dependent 
Non-parametric 
22 and 22 Wilcoxon 
S. R 
0.11 
No difference 910.6/880 473.6/557.4 730/710 
Dilated 
acini  
Sizes of structures correctly 
identified in both PC-CT and 
US 
Dependent 
Parametric 
7 and 7 
 
 
 
Paired- t 
0.13 
No difference 1225/1659 638.7/984.8 241.4/372.2 
Dilated 
acini  
Sizes of structures correctly 
identified in both MRI and US 
Dependent 
Non-parametric 
8 and 8 Wilcoxon 
S. R. 
0.055 
No difference 1121/1516 839.5/996.6 925/1282 
Blood 
vessel 
Sizes of structures correctly 
identified in both Histology and 
PC-CT 
Dependent 
Non-parametric 
28 and 28 Wilcoxon 
S. R. 
0.39 
No difference 323.3/340.4 191.2/117.6 250/300 
Blood 
vessel 
Histology measured sizes of 
structures correctly identified in 
both Histology and PC-CT Vs 
structures misdiagnosed in PC-
CT 
Independent 
Non-parametric 
28 and 5 Mann 
Whitney 
0.035 
Str. Seen in both 
modalities are smaller 
than those mis-
diagnose in PC-CT 
323.3/470.4 191.2/151.9 250/460 
Blood 
vessel 
Histology measured sizes of 
structures correctly identified in 
both Histology and PC-CT Vs 
structures not seen in PC-CT 
Independent 
Non-parametric 
28 and 139 Mann 
Whitney 
0.5 
No difference 323.3/291.5 191.2/143 250/240 
Lymphatic Sizes of structures correctly 
identified in both Histology and 
PC-CT 
Dependent 
Parametric 
14 and 14 Paired-t 
0.08 
No difference 411.4/516.1 160.9/229.7 43/61.4 
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Lymphatic Histology measured sizes of 
structures correctly identified in 
both Histology and PC-CT Vs 
structures misdiagnosed in PC-
CT 
Independent 
Non-parametric 
14 and 10 Mann 
Whitney 
0.023 
Str. Seen in both 
modalities are larger 
than those mis-
diagnose in PC-CT 
411.4/260 160.9/67.33 … 
Lymphatic Histology measured sizes of 
structures correctly identified in 
both Histology and PC-CT Vs 
structures not seen in PC-CT 
Independent 
Non-parametric 
14 and 94 Mann 
Whitney 
0.01 
Str. Seen in both 
modalities are larger 
than those not seen in 
PC-CT 
411.4/299.2 160.9/17.41 410/230 
Lymphatic Sizes of structures correctly 
identified in both Histology and 
MRI 
 
Dependent 
Parametric 
3 and 3 Paired-t 
0.013 
MRI measure bigger 451.7/910.7 157.8/77.47 91.12/44.73 
Lymphatic Histology measured sizes of 
structures correctly identified in 
both Histology and MRI Vs 
structures not seen in MRI 
Independent 
Non-parametric 
3 and 115 Mann 
Whitney 
0.067 
No difference 451.7/305.5 157.8/164.7 440/250 
Glandular 
lobule 
Sizes of structures correctly 
identified in both Histology and 
PC-CT 
Dependent 
Parametric 
13 and 13 Paired-t 
0.064 
No difference 3848/4454 925.3/1087 256.6/301.6 
Glandular 
lobule 
Histology measured sizes of 
structures correctly identified in 
both Histology and PC-CT Vs 
structures not seen in PC-CT 
Independent 
Parametric 
… Unpaired-t 
0.019 
Str. Seen in both 
modalities are larger 
than those not seen in 
PC-CT 
3848/2967 925.3/980.2 256.6/237.7 
Glandular 
area 
Sizes of structures correctly 
identified in both Histology and 
PC-CT 
 
Dependent 
Non-parametric 
14 and 14 Wilcoxon 
S.R. 
0.33 
No difference 3461/2976 1471/1512 3425/2875 
Glandular 
area 
Histology measured sizes of 
structures correctly identified in 
both Histology and PC-CT Vs 
structures misdiagnosed in PC-
CT 
Independent 
Parametric 
… Unpaired-t 
0.99 
No difference 3461/3447 1471/1608 291.2/928.3 
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Glandular 
area 
Histology measured sizes of 
structures correctly identified in 
both Histology and PC-CT Vs 
structures not seen in PC-CT 
Independent 
Non-parametric 
14 and 51 Mann 
Whitney 
0.033 
Str. Seen in both 
modalities are larger 
than those not seen in 
PC-CT 
3461/2640 1471/1352 3425/2230 
 
Fibrous tissue area: There was a total of 204 fibrous tissue area locations (4 locations in each tissue) in 51 tissues whose images from 
all diagnostic modalities were available and tested as indicated (Section 4.5). Of these, 98 spots in US were correctly identified, 106 
were not; in MRI, 97 were correctly identified and 107 were not: in PC-CT, 129 were correctly identified, 75 were not. Comparing 
power in identifying the fibrous tissue area, PC-CT > MRI = US (p<0.05). 
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5.3. Results from the experiment for objective 2: to evaluate the usefulness of a sparse 
view image reconstruction technique (reconstruction with 50% and 25% of the total 
number of the projections) to determine if similar quality images can be obtained 
compared to reconstructions using 100 % of the projections. 
 
Histology identified a total of 312 structures in the 37 tissues used to assess accuracy of sparse 
view PC-CT imaging technique (Table 5.7). 
Table 5.7 Number of structures noted in the histology slides from 37 tissues. 
Structures Count 
Area of adipose tissue 3 
Blood vessel 83 
Dilated acini 79 
Area of glandular tissue 41 
Inflammatory stromal area 8 
Inflammatory glandular area 2 
Lymphatic 71 
Area of mineralization 2 
Glandular lobules 18 
Area of smooth muscle 5 
Grand Total 312 
 
During the evaluation a total of five structures combined to appear as two structures in 100% PC-
CT (two glandular lobules combined and appeared as one glandular lobule and three glandular 
areas combined and appeared as one glandular area). The same was found for the 50% projection 
PC-CT images. In 25% projection PC-CT, none of the three glandular areas were visible andanew 
combined dilated acinus representing three different dilated acini appeared in 25% projection PC-
CT (Figure 5.5). This indicates that the power of resolving two nearby structures is low in 25% 
projection PC-CT, while it is better for 100% and 50% projection PC-CT images. For the sake of 
ease in the statistical analysis ahead, it was decided to handle such a scenario in the same way 
followed for objective one as explained just before table 5.2. 
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             Histology                100% projection                 50% projection            25% projection                      
Figure 5.5 PC-CT images reconstructed from a different number of projections along with the 
histology image of the same plane. 
Table 5.8 Structures present and diagnostic accuracy with 100% projection PC-CT. 
 Total  Agreed with 
histology in 100% 
PC-CT (n, %)  
Mis-diagnosed 
in 100% PC-
CT (n, %)  
Not identified 
in 100% PC-
CT (n, %) 
Structures 
 
n % n % n % 
Area of adipose 
tissue 
3 0 0 0 0 3 100 
Blood vessel 83 11 13.3 3 3.6 69 83.1 
Dilated acini 79 35 44.3 3 3.8 41 51. 9 
Glandular area 41 5 12.2 1 2.4 35 85.4 
Inflamed stromal 
area 
8 0 0 0 0 8 100 
Inflamed glandular 
area 
2 0 0 0 0 2 100 
Lymphatic 71 7 9.9 7 9.9 57 80.2 
Area of 
mineralization 
2 1 50 0 0 1 50 
Glandular lobule 18 7 38. 9 0 0 11 61.1 
Area of smooth 
muscle 
5 4 80 0 0 1 20 
Overall 312 70 22.4 14 4.5 228 73.1 
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In 100 % projection PC-CT, 22.4% of the total structures were correctly identified (Table 5.8). 
Area of smooth muscle was most often correctly identified (four out of five areas), while the area 
of mineralization (one out of two areas) and dilated acini (35 out of 79 dilated acini) were correctly 
identified less frequently. None of the adipose tissue areas, inflamed stromal areas, and inflamed 
glandular areas were correctly identified. 
Table 5.9 Structures present and diagnostic accuracy with 50% projection PC-CT. 
 Total  Agreed with 
histology 
in 50% PC-CT 
(n, %) 
Mis-diagnosed in 
50% PC-CT (n, %) 
Not identified in 
50% PC-CT (n, %) 
Structures 
 
n % n % n % 
Area of adipose tissue 3 0 0 0 0 3 100 
Blood vessel 83 9 10.8 2 2.4 72 86.8 
Dilated acini 79 34 43 6 7.6 39 49.4 
Glandular area 41 1 2.4 0 0 40 97.6 
Inflamed stromal area 8 0 0 0 0 8 100 
Inflamed glandular 
area 
2 0 0 0 0 2 100 
Lymphatic 71 7 9.9 4 5.6 60 84.5 
Area of mineralization 2 1 50 0 0 1 50 
Glandular lobule 18 4 22.2 0 0 14 77.8 
Area of smooth 
muscle 
5 3 60 0 0 2 40 
Overall 312 59 18.9 12 3.9 241 77.2 
           
In 50 % projection PC-CT, 18.9% of the total structures were correctly identified (Table 5.9). Area 
of smooth muscle was the most often correctly identified structure (three out of five areas), while 
the area of mineralization (one out of two areas) and dilated acini (34 out of 79 dilated acini) were 
correctly identified less frequently. As in 100% projection PC-CT, none of the adipose tissue areas, 
inflamed stromal areas, and inflamed glandular areas were correctly identified.  
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Table 5.10 Structures present and diagnostic accuracy with 25% projection PC-CT. 
 Total 
 
  
Agreed with 
histology in 25% 
PC-CT (n, %) 
Mis-diagnosed 
in 25% PC-CT 
(n, %) 
Not identified 
in 25% PC-CT 
(n, %) 
Structures n % n % n % 
Area of adipose tissue 3 0 0 0 0 3 100 
Blood vessel 83 5 6 1 1.2 77 92.8 
Dilated acini 79 19 24.1 0 0 60 75.9 
Glandular area 41 0 0 0  0 41 100 
Inflamed stromal area 8 0 0 0 0 8 100 
Inflamed glandular area 2 0 0 0 0 2 100 
Lymphatic 71 4 5.6 1 1.4 66 93 
Area of mineralization 2 1 50 0 0 1 50 
Glandular lobule 18 1, 5.6 1, 5.6 0, 0 0, 0 17 94.4 
Area of smooth muscle 5 2, 40 2, 40 0, 0 0, 0 3 60 
Overall 312 32 10.3 2 0.6 278 89.1 
         
In 25 % projection PC-CT, 10.3% of the total structures were correctly identified (Table 5.10). 
Area of mineralization was the most often correctly identified structure (one out of two areas), 
while the area of smooth muscle (two out of five areas) and dilated acini (19 out of 79 dilated 
acini) were correctly identified less frequently. As in 100% and 50% projection PC-CT, none of 
the adipose tissue areas, inflamed stromal areas, and inflamed glandular areas were correctly 
identified. Additionally, glandular areas could not be detected when evaluating 25% projection 
PC-CT images.  
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Table 5.11 McNemar χ2 tests to compare the abilities of different % projection PC-CT to 
correctly identify the lesions and structures. 
 Sparse view PC-CT 
techniques compared 
4 Box Values Test 
statistics 
P-
Value 
Result 
Structure 
 
Both techniques + Technique 1 +, 
Technique 2 - 
   
 
 
Technique 1 -, 
Technique 2 + Both techniques - 
   
Overall 
100% PC-CT Vs 
50% PC-CT 53 17 4.3 <0.05 
100% PC-
CT more 
Powerful 
 
 
6 236 
   
Overall 
100% PC-CT Vs 
25% PC-CT 31 39 34.2 <0.05 
100% PC-
CT more 
Powerful 
 
 
1 241 
   
Overall 
50% PC-CT Vs 25% 
PC-CT 31 28 23.3 <0.05 
50% PC-CT 
more 
Powerful 
  1 252    
“+” represents the “correctly identified” category and “-” represents the “not-identified” category of 
structures as previously described. 
In 100% projection PC-CT, 22.4% structures were correctly identified while in 50% and 25% 
projection PC-CT, only 18.9% and 32 10.3% of the total structures were correctly identified, 
respectively (Tables 5.8-5.10). Comparing power in identifying structures, 100% PC-CT > 50% 
PC-CT > 25% PC-CT (P<0.05) (Table 5.11). There was insufficient data to statistically compare 
each kind of structures separately.  
There was no difference found among the 100% PC-CT, 50% PC-CT and 25% PC-CT measured 
sizes for dilated acini, blood vessels and lymphatics (p<0.05; Table 5.12). It was the same for the 
size of glandular lobules measured in 100% and 50% projection PC-CT. There was insufficient 
data regarding glandular lobules from 25% projection PC-CT to statistically compare with others. 
The glandular area also had insufficient data to statistically compare their sizes in between different 
projection PC-CT.  
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Table 5.12 Comparison of the size of different structures measured by different % projection PC-CT techniques. 
Structure Comparison 
between 
Data type Sample 
size 
(pair) 
Test statistics 
P-value 
Result Mean (µm) 
2(former/latter) 
SD (µm) 
(former/
latter) 
Median (for non-
parametric) or SEM 
(for parametric) 
(µm) 
(former/latter) 
Dilated 
acini 
Sizes of structures 
correctly identified in 
both 100% PC-CT 
and 50% PC-CT 
 
 
Non-
parametric 
32 Wilcoxon S. R 
0.23 
No 
difference 
637.8/625.6 216.4/21
4.4 
580/577 
Dilated 
acini 
Sizes of structures 
correctly identified in 
both 100% PC-CT 
and 25% PC-CT 
 
 
Non-
parametric 
17 Wilcoxon S. R 
0.54 
No 
difference 
678.3/689.5 275.8/32
7 
550/580 
Dilated 
acini 
Sizes of structures 
correctly identified in 
both 50% PC-CT and 
25% PC-CT 
 
 
Non-
parametric 
17 Wilcoxon S. R 
0.97 
No 
difference 
690.9/689.5 250.2/32
7 
660/580 
Blood 
vessel 
Sizes of structures 
correctly identified in 
both 100% PC-CT 
and 50% PC-CT 
 
 
Parametric 7 Paired-t 
0.065 
No 
difference 
315.3/291.4 53.75/70.
69 
20.32/26.72 
Blood 
vessel 
Sizes of structures 
correctly identified in 
Parametric 5 Paired-t 
0.87 
No 
difference 
308.4/304.6 64.19/10
1.8 
28.71/45.5 
 
2 Former: Technique mentioned first in each row of second column. Latter: modality mentioned second in each row of second column. 
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both 100% PC-CT 
and 25% PC-CT 
 
 
Blood 
vessel 
Sizes of structures 
correctly identified in 
both 50% PC-CT and 
25% PC-CT 
 
 
Parametric 5 Paired-t 
0.065 
No 
difference 
275.4/304.6 79.75/10
1.8 
35.67/45.5 
Lymphatic Sizes of structures 
correctly identified in 
both 100% PC-CT 
and 50% PC-CT 
 
 
Parametric 5 Paired-t 
0.77 
No 
difference 
441.4/434.8 187/189.
7 
83.62/84.85 
Lymphatic Sizes of structures 
correctly identified in 
both 100% PC-CT 
and 25% PC-CT 
 
 
Parametric 4 Paired-t 
0.46 
No 
difference 
439.3/468.5 215.8/20
6.6 
107.9/103.3 
Lymphatic Sizes of structures 
correctly identified in 
both 50% PC-CT and 
25% PC-CT 
 
 
Parametric 4 Paired-t 
0.43 
No 
difference 
449.8/468.5 215.7/20
6.6 
107.8/103.3 
Glandular 
lobule 
Sizes of structures 
correctly identified in 
both 100% PC-CT 
and 50% PC-CT 
Parametric 3 Paired-t 
0.14 
No 
difference 
4768/3916 345.2/86
4.1 
199.3/498.9 
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5.4.Results from the experiment for objective 3: to quantify the radiation dose received by 
the patient (canine cadavers) during PC-CT imaging and to analyze the corresponding 
dose with a sparse view technique. The goal is to reduce the radiation to the patient 
during PC-CT imaging. 
 
Table 5.13 provides radiation measurements from the ionization chamber and the radiation 
dosimeters. 
Table 5.13 Radiation data generated during PC-CT imaging of canine cadavers in the BMIT-ID 
beamline of the CLS. Dosimeters were located directly in the beam (centre) or 50 mm above or 
below to determine beam scatter. 
Dog Number Dosimeter 
location 
(Centre ones 
were in the 
beam) 
Number of projections 
with the dosimeter 
present in the beam 
(detector side/beam side = 
total) 
Dosimeter 
reading  
(equivalent 
total dose 
(mSv) 
Corrected ionization  
chamber  
reading (equivalent total 
dose (mSv) 
1 Top 
 
3.4 22398.7 
1 Centre 500/0 = 500 82.45 22398.7 
1 Bottom 
 
4.88 22398.7 
2 Top 
 
8.02 26379.7 
2 Centre 480/80 = 560 280.15 26379.7 
2 Bottom 
 
10.34 26379.7 
3 Top 
 
4.49 19268.9 
3 Centre 220/160 = 380 184.57 19268.9 
3 Bottom 
 
5.31 19268.9 
4 Top 
 
8.74 24826.9 
4 Centre 225/400 = 625 592.11 24826.9 
4 Bottom 
 
8.86 24826.9 
5 Centre 530/0 = 530 86.77 34221.4 
Mean and SEM for corrected ionization chamber reading are 25419 mSv and 2507 mSv respectively. 
The dosimeters were exposed to 500 projections for dog 1 and 530 projections for dog 5. They 
recorded 82.45mSv and 86.77mSv equivalent doses respectively (Table 5.13). As these values are 
very close the average of both the doses divided by the projections (84.61mSv, 515 projections) 
indicates the dose is 84.61mSv/515 = 0.1643mSv/projection when a dosimeter is placed behind a 
dog of that size and facing towards the detector, away from the x-ray source. 
Dog 2, dog 3 and dog 4 had been exposed to 480, 220 and 225 projections when facing towards 
the detector and 80, 160 and 400 projections when facing towards the beam and directly exposed 
to the beam. The dose the dosimeters received when facing toward the detector was calculated 
separately from the dose received when facing toward the beam. 
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For dog 2 the number of detector-facing projections = 480. Estimated indirect dose (from 
transmission exposure) for taking 480 projections = 480 x 0.1643 mSv/projection (from above) = 
78.86mSv. Deducting this from the total dose measured by the dosimeter = 280.15mSv – 
78.86mSv = 201.29mSv due to direct exposure of the dosimeter for 80 projections. 
Adjusting exposure of the dosimeter to 2000 projections equivalent, the dose would be 
201.29/80x2000 = 532.25mSv. Similarly, for 2000 projections direct exposure, the doses for 
dog#3 and dog#4 would be 1855.30mSv and 2775.71mSv. The distance corrected ionization 
chamber reading during 2000 projections for dogs 2-4 were 26379.7mGy, 19268.9mGy and 
24826.9mGy respectively. The ionization chambers show readings are approximately five to ten 
times higher than the chip dosimeter reading (Table 5.14). 
Table 5.14 Comparison of radiation data from the Luxel+ dosimeter (central) and the Ionization 
chamber generated during PC-CT imaging of canine cadavers in the BMIT-ID beamline of the 
CLS.  
Dog Number (only 
those dogs with 
dosimeter being 
exposed directly on 
beam) 
Dosimeter 
location 
Calculated reading for central 
dosimeter when exposed for all 2000 
projections directly on the beam 
(equivalent total dose in mSv) 
Corrected ionization  
chamber  
reading (equivalent 
total 
dose in mSv) 
2 Centre 5032.3 26379.7 
3 Centre 1855.3 19268.9 
4 Centre 2775.7 24826.9 
 
The calculated equivalent radiation dose that would be delivered to the cadaver during sparse view 
imaging, differs if the dose is calculated based on the luxel+ dosimeter dose calculations for 2000 
projections, or the ionization chamber reading for 2000 projections (Table 5.15). 
Table 5.15 Calculated radiation dose delivered to the cadaver during sparse view imaging. 
 Based on the luxel+ dosimeter dose calculation  Based on the ionization chamber 
reading 
 50% Projection PC-CT 25% Projection 
PC-CT 
50% Projection 
PC-CT 
25% Projection 
PC-CT 
Dog 2 2516.13mSv 1258.10mSv 13189.85mSv 6594.93mSv  
Dog 3 927.56mSv  463.83mSv  9634.45mSv  4817.23mSv 
Dog 4 1387.85mSv 693.92mSv 12413.45mSv 6206.73mSv 
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5.5.Results from the experiment for objective 4: to develop a human positioning device for 
PC-CT imaging of human prostate in situ. 
 
The final device is designed of x-ray friendly polycarbonate or polyethylene and lightweight 
aluminum (Figure 5.6). The hardware has not currently been constructed as the application for 
CLS shifts to test the hardware during PC-CT imaging was unsuccessful. However, the design is 
finalized and ready for construction. Once constructed, it has the capacity of keeping a phantom 
pelvis up to 50 kg in a stable upright position with less than 6.5 um vertical displacement while 
being rotated for taking projections. It keeps the pelvis tightly positioned in the vertical axis with 
the help of two sets of screws (4 screws/set) and will keep it in the same horizontal plane by 
allowing the pelvis to rest on the bottom surface of the holder. 
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6. Discussion 
 
Overall 
Although the cellular details and visibility of micro-structures required to distinguish the clinical 
conditions of prostate disease such as nuclear and nucleolar enlargement and broaching of basal 
layer, presence of a small gland or group of glands around any nerve bundle and absence of a rim 
of connective tissue between the adjacent glands indicating prostate cancer (Brawer, 2005; 
Humphrey, 2007; Brustmann, 2015), or budding and branching of the duct-acini system and bi-
layered epithelial lining with outer cuboidal cells and inner tall columnar cells indicating BPH 
(McNeal, 1965, 1988), were not achieved with any of the tested imaging modalities, results here 
support synchrotron in-line PC-CT as an imaging modality with high potential for non-invasive 
diagnosis of prostate conditions. MRI and US provided overall less reliable assessments, although 
none of these three modalities appeared to be equal to histology in identifying different structures 
and areas in prostate tissues. Some of the potential sources of errors couldn’t be neglected in 
discussing the results.  One of the potential sources could be the tissue processing techniques and 
handling of the samples throughout the different imaging experiments, e.g. radiation damage of 
the tissue during PC-CT (though noticeable changes were not observed), imperfect parallel slicing 
of gelatin blocks for histological processing, unavoidable probability of minute misalignment 
and/or mismatching of the images from the various methodologies for comparison. The remainder 
of the potential errors have been explained throughout the discussion section in the appropriate 
places. Though histology was considered as a reference modality in this study as considered by 
others (Liu et al., 2009; He et al., 2012; Isebaert et al., 2013) for comparison, it is also not a perfect 
modality itself. Physical alterations such as shearing effect as well as the biochemical effect due 
to fixation, embedding and staining necessary in histology might have potentially hindered the 
correct diagnosis of structures and lesions and their correct size measurement (Taqi et al., 2018).  
In our study, it was found that PC-CT correctly identified 26.4% of the structures while MRI and 
US only identified 6.7% and 2%, respectively. PC-CT was significantly closer, than MRI and US, 
to histology in ability to identify structures and areas correctly. Comparing MRI and US to each 
other, MRI was closer to histology in ability to identify structures and areas correctly. A study on 
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canine prostates at the CLS BMIT-BM beamline had given similar results. In that study, US had 
given very poor structural visualizations, and while MRI produced comparatively better soft-tissue 
contrast, neither modality was able to provide as detailed information as PC-CT could for different 
tissues like urothelial lining, ducts, acini, adipose tissue, muscular structure, fibromuscular stroma, 
etc. (Barboza et al., 2012; Montgomery et al., 2013; Montgomery et al., 2016). In addition, our 
study found that a total of 5.3% of the visible structures appeared combined in PC-CT while in 
MRI and US, it was 38.8% and 30.8% of the total visible structures, respectively indicating higher 
spatial resolution (power of resolving two nearby structures) with PC-CT.  
Possible reasons behind the superiority of PC-CT: In conventional CT, usually, the contrast 
resolution is not considered to be intrinsically good as the attenuation properties of different soft 
tissues are not so different from each other (Lin & Alessio, 2009). However, the total contrast 
achieved here in PC-CT images was improved likely from the additional (phase) contrast generated 
due to the phase shift of the beam as the X-rays pass through the soft tissue and the long-distance 
propagation (1.5 m) of the X-rays between the sample and the detector (Chapman et al., 1997; 
Lewis, 2004a) i.e. through the edge enhancement of different tissues. This phase-based imaging 
is, therefore, more sensitive to even a small difference in densities making it more useful and more 
informative in imaging soft tissue (Chapman et al., 1997; Lewis, 2004b). The spatial resolution we 
measured was 12.49 µm in PC-CT, which is superior to the 1.2 mm resolution usually measured 
with most MRI images (Lin & Alessio, 2009). One of the reasons for the higher spatial resolution 
in PC-CT images was the smaller source size (focal spot) of the beam, because smaller source size 
reduce the penumbral blurring in an X-ray image (Nagesh et al., 2016), giving better image quality 
and higher resolution. The highly collimated and brilliant X-rays also contribute to higher spatial 
resolution (Giuliani et al., 2017). A synchrotron facility is the only place where we can meet all 
these criteria (Izadifar et al., 2017b). Similarly, the smaller pixel size (higher spatial sampling) and 
direct detection system (less blurring) of the CMOS detector (Scott et al., 2012) to capture the 
variation in x-ray intensity due to the refraction and interaction of the beam could contribute to the 
higher spatial resolution and better-quality images in our study. 
Possible reasons behind the differences with MRI: Compared to PC-CT, MRI resulted in 
decreased resolution of the fine structures. The different soft tissue structures were not well 
differentiated in MRI, enabling correct identification of only one quarter of the structures 
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identifiable in PC-CT. Similarly, it was difficult to discern closely located, similar structures, 
which was likely because of decreased spatial resolution (Reddy, 2005; Reeth et al., 2012) and 
larger voxel size resulting in a poorer signal to noise ratio. Almost seven times more structures 
appeared combined in the MRI images compared to PC-CT images. But just the image resolution 
might not be the reasons behind the results with MRI compared to PC-CT. In MRI, the 
interpretation can vary depending on the type of software and machine being used as well as the 
experience of the examiner. We had access to a 1.5 Tesla machine for our imaging but the use of 
a MRI machine with a stronger magnetic field would have given a greater signal to noise ratio and 
so the better spatial resolution and soft-tissue contrast (Lawrentschuk & Fleshner, 2009; Thompson 
et al., 2013; Pedler, et al., 2015). If we were performing in-vivo physiological imaging there would 
be an option to use spin-echo/anatomical sequences along with advanced functional sequences 
such as diffusion-weighted imaging and dynamic contrast-enhanced imaging for better 
visualization and interpretation of the pathological condition. However, our study was on excised 
tissue therefore we were limited to using only spin-echo/anatomical sequences (T1 ad T2) which 
could also be one of the reasons our results were inferior to PC-CT. The T1 and T2 weighted 
sequences are able to identify mostly the anatomic abnormalities rather than the physiologically 
altered pathology. Underlying diffusivity (with blood, water, or any kind of fluid) would be more 
appreciated in diffusion weighted MRI sequences than the anatomical sequences. Moreover, the 
spin-echo/anatomical MRI sequences are not good in differentiation of benign and malignant 
neoplastic conditions, mainly because of being poor in distinguishing lymphatic tissue (which is 
usually the first tissue to be metastasized) from tumors due to similar relaxation times and proton 
densities. It is also challenging to differentiate the cystic lesions from solid lesions without the 
adequate fat suppression possible with the spin-echo/anatomical sequences MRI. (Beets-Tan, 
2010; Ha et al., 2017; Hamm et al., 2007).  
Possible reasons behind the differences of US: The use of US resulted in the most reduced image 
quality in terms of identifying different structure and pathological lesions inside prostate tissues. 
As indicated earlier, US only identified 2% of the total structures correctly and out of those 
correctly identified structures, 30.8% structures appeared combined with similar other structures. 
One of the reasons behind this result from US, as compared to PC-CT and MRI, could be a small 
difference (less than 10%) of the speed of the ultrasound in the different soft tissues (Hayward, 
2012). The small difference in ultrasound velocity accounts for only a small difference in acoustic 
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properties (echos) of the tissues that results in poor contrast in an image to differentiate different 
structures (Tole et al., 2005). Similarly, too many inherent artifacts in US images could be other 
reasons for the weaker diagnostic quality images in our study. Some of these artifacts are beam 
width artifact (where the highly refractive object located within the wide beam but outside of the 
transducer margin at the depth below the focal point will be displayed as if the object is located 
within the narrow imaging plane of transducer), reverberation artifact (where the US image is 
formed assuming an echo returned from multiple bouncing in between multiple parallel layers of 
tissues as an echo reflected from a single reflection) and speed displacement artifact (where the 
US imaging system processes an image assuming the same constant speed of the ultrasound waves 
(1540 m/sec) even though the ultrasound has different velocities in different tissue) (Feldman et 
al., 2009).   Moreover, there is an unavoidable probability that the chosen US images might be a 
non-exact match to the histology images because of the step size limitation of US machine used. 
It could only capture images 40 µm apart from each other, missing the areas in between.  Similarly, 
image resolution does not stay the same throughout the region between the surface and depth of 
the tissue. Axial resolution (ability to discern two adjacent structures that are longitudinally 
parallel to the ultrasound wave) deteriorates for the deeper parts in the image (Ng & Swanevelder, 
2011). Also, the interpretation can vary depending on the type of software and machine being used 
as well as the experience of the examiner. Placing the probe in a slightly different position and 
slightly different angle will give a different view. Similarly, the different adjustment of gain, 
contrast, focal points affects the images produced (Chu et al., 2014; Tole et al., 2005; Wiafe & 
Badu-Peprah, 2019). All of these factors might have played in making US images less efficient in 
identifying and characterizing the different structures and pathological lesions in our study. Beside 
the unavoidable inherent artifacts, the whole experiment and images evaluation were done by a 
single person, with same machine and setting to lessen the errors as much as possible.  
The possible error from all the modalities could be reduced to some extent if whole prostate glands 
could have been used instead of the TURP tissues. A single bigger tissue mass would have had a 
firmer integrity than the gelatin, and so possibly would have resulted in less misalignment during 
sample processing for the different modalities, especially histology. Also, for the histological 
examination, a larger area of the prostate to evaluate may have made the diagnosis of different 
pathological lesions easier by evaluating focal as well as surrounding areas.   
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Structures and their size measurement: In PC-CT, the area of mineralization was the most often 
correctly identified (in agreement with histology) structure but none of the mineralization was 
identified in MRI and US. This finding is in agreement with what we expect from clinical X-ray 
imaging (regular radiographs or CT), MRI and US. We can expect very distinct high-density spots 
from mineralized structures even in regular radiographs. CT is sensitive to the mineralized 
structures (Freire et al., 2018) such that it is almost impossible to miss any such structures in the 
examination of an image. We found the same pattern here in PC-CT. This result might be because 
of the high absorption coefficient of the mineralized tissue along with the X-ray phase shift that 
propagates during PC-CT imaging. On the contrary, we didn’t identify any of the mineralization 
in the MRI or US imaging. The variation in the signal intensities in the anatomical sequences, 
especially for calcifications, can give misleading appearances in MRI such as inflammatory spots 
or fluid signals around them resulting in the calcifications remaining unnoticed. Similarly, the 
acoustic shadowing (the dark area just behind a highly sound-reflective or absorbing object hinders 
the US in making the correct interpretation for mineralized structures and their surroundings 
(Freire et al., 2018; Nörenberg et al., 2016; Rupp, Seil, & Kohn, 1998). These factors could 
contribute to the poor outcomes with MRI and US in our study. With the MRI, only cysts, 
lymphatics, and blood vessels were correctly identified. These structures most of the time, are 
hollow, and if not, the inner cavity is occupied with fluid and is not a solid structure.  This implies 
that the anatomical sequence MRI we used was able to identify only those structures which have 
a very drastic difference in physical nature between the outer tunic and the inside portion.  In the 
US, cysts were the only kind of structure correctly identified.  
Comparison of the sizes of different structures from different imaging modalities was one of the 
goals of the study. Reliability in giving the accurate measurement of different structures and 
lesions is important for clinical purposes, if PC-CT is to be made clinically applicable in future. 
There was no difference in the size of cysts measured from histology, PC-CT, MRI, and US, which 
signifies that the size measurements of detectable cysts do not differ in different modalities.  These 
cysts that were visible in histology and in any of the imaging modalities (PC-CT, MRI, US) are 
larger than the cysts detectable only in histology. The visible histological presence of these small 
cysts which were undetectable in the other imaging modality but were in the histology suggests 
that smaller structures are less likely to be visible in these imaging modalities than in histology, 
and so would be missed in a non-histological assessment. 
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Sparse view PC-CT: One method to image with a low dose of radiation and in a short timeframe 
is to decrease the projection numbers while imaging, i.e. sparse view technique. We had imaged 
our samples with 2250 projections but also reconstructed the PC-CT images with equally spaced 
1125 and 562 projections. With 100% projection PC-CT, we correctly identified 22.4% of the total 
structures while in 50% and 25% projection PC-CT, it was only 18.9% and 32 10.3% respectively. 
The 100% projection PC-CT was found significantly more powerful than 50% and 25% projection 
PC-CT and 50% projection PC-CT was found powerful than 25% Projection PC-CT in correctly 
diagnosing structures and areas. Some of the reasons might be the serious streak artifacts and 
blurring that were evident  in the PC-CT images reconstructed from a lesser number of projections 
(Barrett & Keat, 2004; Melli et al., 2016). Low signal to noise ratio might be another reason (Lin 
et al., 2018). Moreover, in our study, a total of 6.8% and 8.1% of the visible structures appeared 
combined in 100% and 50% PC-CT respectively while in 25% PC-CT, 14.3% of the visible 
structures appeared combined. This indicates the power of resolving two nearby structures is 
almost the same in 100% and 50% PC-CT but is almost half in 25% PC-CT. This suggests that 
the100% and 50% projection PC-CT resulted in a similar amount of phase-contrast while the 50% 
projection PC-CT was providing a comparatively low amount of phase-contrast, not sufficient 
enough to discern two closely placed, similar structures as with the 100% and 50% projection PC-
CT (Izadifar et al., 2017a). Additionally, with 25% projection PC-CT, we could not detect any of 
the glandular areas which were otherwise detected in 100% and 50% projection PC-CT. All of 
these findings are in agreement with the findings from a previous study conducted at the CLS 
Biomedical Imaging and Therapy bending-magnet (BMIT-BM) beam-line accessing the 
implanted cardiac patches on a rat heart (Izadifar et al., 2017a). In that study, CT reconstructions 
were separately done with 3000, 1500, 1000 and 750 projections. They observed that the 
anatomical features in tomographic images were well visualized even in the image from low 
projection numbers, i.e. 1500, but it was difficult to identify the microstructure with 1000 and 750 
projections.  
 
Radiation dose: Our findings support that the PC-CT is closer-to-histology imaging technique 
than the other conventional medical imaging techniques for imaging prostate tissues. However, 
that doesn’t solely define the usefulness of the technique in clinical use. Another important factor 
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that needs to be considered before thinking to implement the imaging technique for clinical use is 
the dose imparted while imaging. Though the image contrast developed in phase contrast imaging 
is not due to the radiation absorption by the tissue that is imaged, the amount of radiation absorbed 
is definitely an issue of concern. If the technique is depositing a harmful radiation dose while 
imaging, then it will be a significant limitation of PC-CT and it is not useful beyond ex-vivo 
imaging. While we did not measure the radiation imparted in our TURP tissue samples while 
imaging, we did collect dose data while imaging canine prostates in-situ in the BMIT-ID beamline.  
A dose the dosimeter would record when placed behind a medium sized dog (~28 kg) such that 
the x-rays struck the dosimeter only after they pass through the cadaver is 0.16mSv/projection 
(from the calculation done in the methodology section). The delivered dose would be 
1.11mSv/projection (averaged all the values of the third column of Table 5.14 and divided by 
2000) when the dosimeter is placed directly in the beam. This indicates that a dosimeter would be 
radiated 6.9 times more whenever it was directly exposed to the beam compared to when the beam 
passed through the cadaver prior to hitting the dosimeter. 
 
It was found that the Luxel+ dosimeter recorded an average equivalent radiation dose imparted in 
a medium-sized dog during PC-CT imaging of one view of 7.8 mm height with 2000 projections 
in the CLS BMIT-ID beamline of 3,221.1 mSv. This is equal to an effective dose of 1,481.7 mSv 
(taking into account the compartment factors (wc) of 0.460 for the abdomen/pelvis out of 1.000 
for the whole body (ICRP, 2007). However, in human medicine, standard clinical x-ray 
examinations of various body parts usually deposit a radiation dose ranging from 0.01-10 mSv, 
while a standard clinical CT examination deposits a dose ranging between 2-20 mSv (Mettler et 
al., 2008). In a study performed in 1,119 adult human patients, it was found that the median 
effective dose for a routine abdomen-pelvis CT was 15 mSv (Smith-Bindman et al., 2009). 
Compared to these values, the doses delivered in the synchrotron PC-CT imaging has been found 
to be very high. Even higher doses were recorded by the ionization chambers simultaneously used 
with Luxel+ dosimeters. Average reading of the iodination chambers was 10.9Sv effective dose 
(23.5 Gy absorbed dose) which is approximately seven times higher than the chip dosimeter 
reading. The reason behind the higher reading by ionisation chambers has been difficult to find 
and is yet unknown. Similar high doses had been recorded in another related study of canine 
imaging with synchrotron PC-CT. The imaging was conducted in live dogs of an average weight 
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of 28kg at the CLS. The average effective radiation dose of 10120 mSv (22 Gy absorbed dose) 
was recorded by an ion chamber for 2000 projections over 180° (Cavalca Cardoso, 2019).  
 
In our study, it was found that the effective dose would be reduced to half i.e., 740.9 mSv and one 
fourth i.e. 370.4 mSv if we performed sparse view imaging i.e. 50% projection PC-CT and 25% 
projection PC-CT, respectively. This is somewhat close in agreement with the finding of a study 
of accessing the implanted cardiac patches on a rat heart (Izadifar et al., 2017a). In this study, 
different 3000, 1500, 1000 and 750 projections images were collected throughout the 180-degree 
rotation. The absorbed X-ray dose (measured by ionization chamber) imparted while imaging with 
3000 projections with 25 KeV monochromatic beam in the BMIT-BM beamline was 256mSv. 
With 50% projection PC-CT and 25% projection PC-CT, it was reduced to 128 mSv and 64 mSv 
respectively. But even after reducing the dose to one fourth, the doses recorded in these studies are 
still hazardous with the potential to induce cancer later in life in approximately 0.5 % of the patients 
if the imaging was done in humans (CCOHS, 2019). These findings indicate that synchrotron PC-
CT imaging, though superior in providing high-resolution image quality, needs to be further 
studied to make it clinically applicable. Besides the extremely high radiation dose there are other 
major difficulties and limitations in transforming the synchrotron inline PC-CT technique into a 
clinical diagnostic tool for live human imaging.  These include a small field of view resulting in 
longer imaging times for a larger area, difficulties in keeping the human body in an upright 
position, associated vertical movement and motion artifact and the interference caused by the 
denser structures such as vertebra and other bones.  
 
Pelvic holder: We designed a pelvis holder made up of polycarbonate/polyethylene containers of 
41.2 cm internal diameter and the rest of the parts were designed to be made up of aluminum. It 
was designed to use for the simulation of the in-vivo imaging of the human prostate as a next step 
research of this ex-vivo prostate tissue imaging. Due to additional imaging shifts not being 
available at the CLS (due to the long shut down of the CLS facility from the technical problem, 
and due to the high numbers of research proposal applicants for next imaging cycle after the facility 
came into operation), we didn’t construct the hardware. But this design is complete and ready to 
be constructed and tested to determine if it will perform as designed during PC-CT imaging of a 
human pelvis/phantom at the CLS. 
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7. Conclusion 
 
7.1.Overview 
 
Since the advent of synchrotron X-ray imaging, there has not been one study done on human 
prostate research tissue. The main objective of this thesis was to examine the ability of 
synchrotron-based in-line propagation phase-contrast computerized tomography (PC-CT) to 
characterize and differentiate various structural features and pathological lesions within human 
prostatic tissue samples in comparison to US, MRI, and histology. PC-CT is proven to be a 
significantly powerful (closer-to-histology) imaging technique compared to MRI and US in 
identifying mini-structures and areas within human prostate tissue samples. PC-CT identified 
almost four times and 15 times more structures than MRI and US respectively. Power to resolve 
nearby similar structures was also higher in PC-CT indicating higher spatial resolution and edge 
enhancement. Area of mineralization and cystic acini were the most often correctly identified 
pathological structures in PC-CT. It was also found that the size of a structure matters whether it 
will be visualized in PC-CT, MRI, and US. Smaller sized structures are less likely to appear in 
these imaging modalities.  
 
PC-CT images from a 2250 projections (100%) are superior in image quality than images from 
1125 (50%) and 562 (25%) projection PC-CT, with 50% projection PC-CT more powerful than 
25% PC-CT, in terms of visualizing the different structures and areas. There was a drastic 
difference in image quality between 50% projection PC-CT and 25% projection PC-CT than 
between 100% projection PC-CT and 50% projection PC-CT. The pattern was same in terms of 
power of resolving nearby similar structures too. This indicates we could reduce to a lower number 
of projections to decrease the radiation dose imparted in specimens but at the same time, but there 
will be a trade-off with image quality.  
 
Though the image quality achieved with the synchrotron PC-CT imaging seems promising for 
future development for clinical use, the radiation dose imparted during the imaging was very high 
compared to a standard clinical CT examination. Even the less powerful 50% or 25% projection 
PC-CT were calculated to provide doses above the acceptable limit and considered hazardous.  
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7.2.Future directions 
 
The results (images, corresponding data and their analysis) from this work indicate that 
synchrotron radiation-based inline PC-CT is a promising technique that offers improved non-
invasive diagnostic imaging of prostate tissue. Our results give more confidence for future 
researchers to conduct studies into in-vivo prostate imaging along with the evaluation of the 
corresponding radiation dose to evaluate the usefulness of the PC-CT technique and also with the 
attempt to reduce the radiation doses for clinical application in future. 
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9. Appendices 
 
9.1.Appendix 1: Sample preparation and histology: 
 
Before starting the histological preparations for our samples, the gelatin cylinder containing the 
TURP samples had to be taken out of each jar and sliced into small slices of approximately 3 mm 
thick (room temperature). It was critical to slice them exactly perpendicular to the length of the jar 
so that the slices would be in the same plane as the PC-CT and MRI images previously collected.  
For that, a metal slicing holder was specially designed and constructed (Figure 9.1; RMD 
Engineering Inc., Saskatoon, SK). It used metal fins to create slicing slits approximately 3 mm 
apart from one another that were used to guide the R35 type, microtome blades (Feather Safety 
Razor Co., Ltd Osaka, Japan) during slicing. Temporary plastic spacers were placed in each of those 
slits and the inner part of the slicer was wrapped with parafilm to prevent the liquid gelatin leaking 
out from the slicer once the liquid gelatin would be poured over the gelatin cylinder in the slicer 
(to positioning the gelatin cylinder firmly in the slicer cavity). The gelatin cylinder was placed 
inside the slicer with its length perpendicular to the slicing slits. At that time, the top and bottom 
ends of the gelatin cylinder in the slicer were noted down on outer surface of the slicer so that the 
top-bottom orientation of the gelatin cylinder wouldn’t be missed.  
 
 
 
 
 
Figure 9.1 Metal slicer (green arrow) with yellow plastic spacers (black arrow), parafilm (yellow 
arrow) and the gelatin cylinder (red arrow) containing the TURP samples.  
Fresh liquid gelatin was then poured into the slicer covering the whole gelatin cylinder. After 
solidifying, the entire gelatin block within the slicer and with the tissues at the centre was firm 
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enough for slicing. The plastic spacers were removed, and the microtome blade was used to cut 
the gelatin block into slices of ~3 mm (Figure 9.2).  
 
 
 
 
Figure 9.2 Slicing a gelatin block (red arrow) with microtome blade (yellow arrow) in metal 
slicer (black arrow) 
 
 
 
 
 
 
Figure 9.3 Sliced gelatin block taken out from the slicer. 
The whole sliced block was taken out of the slicer as a single unit and each of the slices were kept 
in a row from top to bottom serially (Figure 9.4). The same procedure was followed for the rest of 
the gelatin blocks. Thirteen samples were cut into the ~ 3 mm slices and the remaining four (T1a, 
T3a, T6a, T9a; Table 4.1) were heavily lacerated and turned into useless pieces due to the 
liquefaction from the bacterial contamination. In this way, 36 slices were made from 13 samples. 
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Figure 9.4 Slices of a sample in a row from top to bottom serially.  
 
The excess gelatin from all sides was trimmed as much as possible to allow the samples to fit into 
M490 – HISTOSETTE® I Tissue cassettes (Simport Scientific, Bernard-Pilon Beloeil, Quebec, 
Canada). Blue ink (Mrs. Stewart’s® Liquid Laundry Bluing, Mrs. Stewart’s Bluing Corp, 
Bloomington, Minnesota, USA) marking was done on the same surface and the same direction in 
all slices to keep the relative orientation of slices with each other and the original gelatin bock.  
The thickness of each slice was then measured with a Vernier scale (product name: Vernier Caliper, 
Plastic, # 1216Y22 by Thomas Scientific, Swedesboro, New Jersey, USA) by averaging the four 
thicknesses from four sides (Figure 9.5).  
 
 
 
 
 
 
Figure 9.5 Ink marked slices (black arrow) in a serial order with their thicknesses in millimetres 
(red arrow).  
 
After that, each slice was transferred into a separate histology cassette (M490 – HISTOSETTE® 
I, Simport Scientific, Bernard-Pilon Beloeil, Quebec, Canada) and each of them were labeled with 
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the sample number and slice number. The same procedure was applied for all samples. All the 
cassettes were kept in 10% buffered formalin and submitted to Prairie Diagnostic Services (PDS), 
University of Saskatchewan for paraffin embedding and creation of the blocks. Clear instructions 
to ensure the proper orientation of each slice into the paraffin block was also submitted in a written 
form to the PSD. Surgipath Paraplast® (Leica Biosystems, Wetzlar, Germany) was used for 
paraffin embedding/block creation which has a melting temperature of 56°C.  
After receiving all 36 paraffin blocks from the 13 samples back from PDS, the rest of the 
procedures were conducted in the histology laboratory of the Department of Veterinary 
Biomedical Sciences in WCVM. It was decided to do serial microtome sectioning of the paraffin 
blocks and collect one section every 20 sections; each section was 5µm thick.  
Sectioning was done with the a Microm® Microtome (ThermoFisher Scientific, Waltham, 
Massachusetts, U.S.). The gelatin in the paraffin blocks became very hard after all the histological 
processing and it was a challenge to section the blocks as the hard gelatin was cracking while 
sectioning. After multiple practices on trial samples a solution was found to overcome the problem. 
The blocks were cooled by placing into crushed ice and water (5-6 minutes) for cutting every 20 
sections (i.e. to get one section as it was decided to collect one section out of every 20 sections 
cut). Another challenge was the wrinkles in the sections even after making the sections float in a 
warm water bath as usually adapted in regular histology procedure to prevent wrinkles. This was 
because of the difference in the rate of expansion of the tissue (at the center), gelatin (in between 
tissue and paraffin) and paraffin (outermost layer). After multiple trials, it was determined that 
using about a 15% ethanol solution at room temperature for floating the sections prior to floating 
them into a warm water bath of ~47°C reduces the wrinkles. After placing the sections onto glass 
slides and labeling them, they were kept on a warm plate (37°C) horizontally for at least 20 minutes 
to fix the tissues onto the slides. Then the slides were transferred to the slide rack, incubated (60°C, 
60 min), and then removed and cooled to a room temperature for at least 30 minutes before 
staining. Different steps followed are summarized as follow:  
1) Paraffin blocks were cooled by placing into crushed ice and water for cutting every 20 sections, 
2) Sections were floated into 15% ethanol solution,  
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3) Floated again into a warm water bath of ~47°C,  
4) Scooped the sections into glass slides,  
5) Slides kept on a warm plate (37°C) horizontally for at least 20 minutes,  
6) Slides were transferred to the slide rack and incubated at 60°C for 60 min,  
7) Slides were removed form incubator and cooled to a room temperature.  
Tissues were stained in hematoxylin and eosin (H&E; modified from Slaoui & Fiette, 2011) at 
room temperature with steps mentioned as below (Figure 9.6). A vertical slide rack (M90512DGY, 
Simport™ Scientific, Bernard-Pilon Beloeil, Quebec) was used to move slides containing the 
tissues from one solution to another.  
Xylene 1 (Fisher Scientific, Fair Lawn, New Jersey, USA): 2 minutes 
Xylene 2: 2 minutes 
100% Ethanol (Greenfield Global Inc., Toronto, Canada): 2 minutes 
100% Ethanol: 2 minutes 
95% Ethanol: 2 minutes 
95% Ethanol: 2 minutes 
Running deionized water: 3 Minutes 
Hematoxylin (SH26-4D, LOT 153233, Harris Modified, Fisher Chemical, Ottawa): 4 minutes 
Running deionized water: 3 minutes 
0.3% Acid alcohol (1 ml conc. HCL (Fisher Chemical) in 333.33 ml 70% alcohol): 30 seconds 
Running deionized Water: 3 minutes 
Eosin Y 1% Solution in water (SE23-500D, LOT 183228, Fisher Chemical, Ottawa): 4 minutes 
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Running deionized water: 30 seconds 
95% Ethanol: 1 minute 
95% Ethanol: 1 minute 
100% Ethanol: 1 minute 
Xylene 1: 1 minute 
Xylene 2: 2 minutes 
 
 
 
 
 
Figure 9.6. Staining jars in serial order. 
 
Wet slides were then permanently mounted with Permount™ mounting medium (Fisher 
Chemical™, Pittsburgh, USA) by placing coverslip over it and stored horizontally to dry (Figure 
9.7).  
 
 
 
 
Figure 9.7 Mounted slides on a rack for drying.  
